

# QUEST DIAGNOSTICS INC (DGX)

## 10-Q

Quarterly report pursuant to sections 13 or 15(d)

Filed on 07/27/2011

Filed Period 06/30/2011

THOMSON REUTERS ACCELUS™



THOMSON REUTERS

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2011  
Commission file number 001-12215

**Quest Diagnostics Incorporated**

Three Giralda Farms  
Madison, NJ 07940  
(973) 520-2700

**Delaware**  
(State of Incorporation)

**16-1387862**  
(I.R.S. Employer Identification Number)

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

As of July 21, 2011, there were outstanding 158,286,303 shares of the registrant's common stock, \$.01 par value.

---

**PART I - FINANCIAL INFORMATION**

	Page
<b>Item 1. Financial Statements</b>	
Index to consolidated financial statements filed as part of this report:	
<a href="#"><u>Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2011 and 2010</u></a>	2
<a href="#"><u>Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010</u></a>	3
<a href="#"><u>Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2011 and 2010</u></a>	4
<a href="#"><u>Consolidated Statements of Stockholders' Equity for the Six Months Ended June 30, 2011 and 2010</u></a>	5
<a href="#"><u>Notes to Consolidated Financial Statements</u></a>	6
<b>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</b>	
Management's Discussion and Analysis of Financial Condition and Results of Operations	32
<b>Item 3. Quantitative and Qualitative Disclosures About Market Risk</b>	
See Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations"	44
<b>Item 4. Controls and Procedures</b>	
Controls and Procedures	44

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
**FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2011 AND 2010**  
**(unaudited)**  
**(in thousands, except per share data)**

	Three Months Ended June 30,		Six Months Ended June 30,	
	2011	2010	2011	2010
<b>Net revenues</b>	\$ 1,903,201	\$ 1,874,727	\$ 3,724,778	\$ 3,680,230
<b>Operating costs and expenses:</b>				
Cost of services	1,104,394	1,078,971	2,201,392	2,145,344
Selling, general and administrative	462,789	419,412	910,647	850,145
Amortization of intangible assets	18,592	9,270	28,441	18,629
Other operating expense, net	572	1,180	236,484	1,656
<b>Total operating costs and expenses</b>	<b>1,586,347</b>	<b>1,508,833</b>	<b>3,376,964</b>	<b>3,015,774</b>
<b>Operating income</b>	<b>316,854</b>	<b>365,894</b>	<b>347,814</b>	<b>664,456</b>
<b>Other income (expense):</b>				
Interest expense, net	(46,581)	(36,367)	(84,510)	(72,322)
Equity earnings in unconsolidated joint ventures	7,869	7,385	15,568	15,349
Other (expense) income, net	(346)	(7,119)	1,862	(1,107)
<b>Total non-operating expenses, net</b>	<b>(39,058)</b>	<b>(36,101)</b>	<b>(67,080)</b>	<b>(58,080)</b>
<b>Income from continuing operations before taxes</b>	<b>277,796</b>	<b>329,793</b>	<b>280,734</b>	<b>606,376</b>
<b>Income tax expense</b>	<b>105,762</b>	<b>125,651</b>	<b>154,988</b>	<b>231,029</b>
<b>Income from continuing operations</b>	<b>172,034</b>	<b>204,142</b>	<b>125,746</b>	<b>375,347</b>
<b>Loss from discontinued operations, net of taxes</b>	<b>(507)</b>	<b>(266)</b>	<b>(881)</b>	<b>(318)</b>
<b>Net income</b>	<b>171,527</b>	<b>203,876</b>	<b>124,865</b>	<b>375,029</b>
<b>Less: Net income attributable to noncontrolling interests</b>	<b>8,384</b>	<b>9,261</b>	<b>15,583</b>	<b>17,966</b>
<b>Net income attributable to Quest Diagnostics</b>	<b>\$ 163,143</b>	<b>\$ 194,615</b>	<b>\$ 109,282</b>	<b>\$ 357,063</b>
<b>Amounts attributable to Quest Diagnostics' stockholders:</b>				
Income from continuing operations	\$ 163,650	\$ 194,881	\$ 110,163	\$ 357,381
Loss from discontinued operations, net of taxes	(507)	(266)	(881)	(318)
<b>Net income</b>	<b>\$ 163,143</b>	<b>\$ 194,615</b>	<b>\$ 109,282</b>	<b>\$ 357,063</b>
<b>Earnings per share attributable to Quest Diagnostics' common stockholders - basic:</b>				
Income from continuing operations	\$ 1.03	\$ 1.08	\$ 0.68	\$ 1.98
Loss from discontinued operations	—	—	—	—
<b>Net income</b>	<b>\$ 1.03</b>	<b>\$ 1.08</b>	<b>\$ 0.68</b>	<b>\$ 1.98</b>
<b>Earnings per share attributable to Quest Diagnostics' common stockholders - diluted:</b>				
Income from continuing operations	\$ 1.02	\$ 1.07	\$ 0.68	\$ 1.96
Loss from discontinued operations	—	—	(0.01)	—
<b>Net income</b>	<b>\$ 1.02</b>	<b>\$ 1.07</b>	<b>\$ 0.67</b>	<b>\$ 1.96</b>
<b>Weighted average common shares outstanding:</b>				
Basic	157,607	178,920	159,548	179,570
Diluted	159,352	180,760	161,278	181,572
<b>Dividends per common share</b>	<b>\$ 0.10</b>	<b>\$ 0.10</b>	<b>\$ 0.20</b>	<b>\$ 0.20</b>

The accompanying notes are an integral part of these statements.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**  
**JUNE 30, 2011 AND DECEMBER 31, 2010**  
(in thousands, except per share data)

	<b>June 30,</b>	<b>December 31,</b>
	<b>2011</b>	<b>2010</b>
	(unaudited)	
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 184,218	\$ 449,301
Accounts receivable, net of allowance for doubtful accounts of \$244,156 and \$228,917 at June 30, 2011 and December 31, 2010, respectively	929,372	845,299
Inventories	87,967	76,572
Deferred income taxes	166,739	142,470
Prepaid expenses and other current assets	109,659	91,775
Total current assets	1,477,955	1,605,417
<b>Property, plant and equipment, net</b>	820,593	834,376
<b>Goodwill</b>	5,816,969	5,101,938
<b>Intangible assets, net</b>	1,082,171	796,405
<b>Other assets</b>	233,503	189,494
<b>Total assets</b>	\$ 9,431,191	\$ 8,527,630
<b>Liabilities and Stockholders' Equity</b>		
<b>Current liabilities:</b>		
Accounts payable and accrued expenses	\$ 998,682	\$ 865,272
Short-term borrowings and current portion of long-term debt	994,675	348,996
Total current liabilities	1,993,357	1,214,268
<b>Long-term debt</b>	3,332,931	2,641,160
<b>Other liabilities</b>	654,307	618,077
<b>Stockholders' equity:</b>		
Quest Diagnostics stockholders' equity:		
Common stock, par value \$0.01 per share; 600,000 shares authorized at both June 30, 2011 and December 31, 2010; 214,597 shares and 214,173 shares issued at June 30, 2011 and December 31, 2010, respectively	2,146	2,142
Additional paid-in capital	2,317,074	2,311,421
Retained earnings	3,945,037	3,867,420
Accumulated other comprehensive income	34,043	10,626
Treasury stock, at cost; 56,385 shares and 43,456 shares at June 30, 2011 and December 31, 2010, respectively	(2,869,150)	(2,158,129)
Total Quest Diagnostics stockholders' equity	3,429,150	4,033,480
Noncontrolling interests	21,446	20,645
Total stockholders' equity	3,450,596	4,054,125
<b>Total liabilities and stockholders' equity</b>	\$ 9,431,191	\$ 8,527,630

The accompanying notes are an integral part of these statements.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE SIX MONTHS ENDED JUNE 30, 2011 AND 2010**  
(unaudited)  
(in thousands)

	Six Months Ended June 30,	
	2011	2010
<b>Cash flows from operating activities:</b>		
Net income	\$ 124,865	\$ 375,029
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	136,084	126,307
Provision for doubtful accounts	145,985	148,403
Deferred income tax provision (benefit)	8,890	(3,702)
Stock-based compensation expense	35,192	28,575
Excess tax benefits from stock-based compensation arrangements	(4,786)	(4)
Provision for special charge	236,000	—
Other, net	6,430	11,266
Changes in operating assets and liabilities:		
Accounts receivable	(194,057)	(193,168)
Accounts payable and accrued expenses	(74,546)	(84,590)
Settlement of special charge	(241,000)	—
Income taxes payable	39,323	41,780
Other assets and liabilities, net	1,703	(1,512)
<b>Net cash provided by operating activities</b>	<b>220,083</b>	<b>448,384</b>
<b>Cash flows from investing activities:</b>		
Business acquisitions, net of cash acquired	(1,136,380)	—
Sale of securities acquired in business acquisition	213,541	—
Capital expenditures	(78,624)	(88,848)
Increase in investments and other assets	(6,503)	(3,196)
<b>Net cash used in investing activities</b>	<b>(1,007,966)</b>	<b>(92,044)</b>
<b>Cash flows from financing activities:</b>		
Proceeds from borrowings	2,433,329	—
Repayments of debt	(1,108,786)	(1,487)
Purchases of treasury stock	(835,001)	(425,773)
Exercise of stock options	97,216	40,174
Excess tax benefits from stock-based compensation arrangements	4,786	4
Dividends paid	(32,930)	(36,430)
Distributions to noncontrolling interests	(16,850)	(16,830)
Other financing activities	(18,964)	(2,366)
<b>Net cash provided by (used in) financing activities</b>	<b>522,800</b>	<b>(442,708)</b>
<b>Net change in cash and cash equivalents</b>	<b>(265,083)</b>	<b>(86,368)</b>
<b>Cash and cash equivalents, beginning of period</b>	<b>449,301</b>	<b>534,256</b>
<b>Cash and cash equivalents, end of period</b>	<b>\$ 184,218</b>	<b>\$ 447,888</b>

The accompanying notes are an integral part of these statements.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**  
**FOR THE SIX MONTHS ENDED JUNE 30, 2011 AND 2010**  
**(unaudited)**  
**(in thousands)**

**Quest Diagnostics Stockholders' Equity**

	Shares of Common Stock Outstand- -ing	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Compre- -hensive Income	Treasury Stock, at Cost	Compre- -hensive Income	Non- -controlling Interests	Total Stock- -holders' Equity
<b>Balance, December 31, 2010</b>	170,717	\$ 2,142	\$2,311,421	\$3,867,420	\$ 10,626	\$(2,158,129)	\$	20,645	\$ 4,054,125
Net income				109,282			\$109,282	15,583	124,865
Currency translation					26,474		26,474		26,474
Market valuation, net of tax benefit of \$1,020					(1,596)		(1,596)		(1,596)
Net deferred loss on cash flow hedges					(1,461)		(1,461)		(1,461)
Comprehensive income							\$132,699		
Dividends declared				(31,665)					(31,665)
Distributions to noncontrolling interests								(16,850)	(16,850)
Issuance of common stock under benefit plans	972	7	1,274			8,770			10,051
Stock-based compensation expense			33,418			1,774			35,192
Exercise of stock options	2,240		(16,220)			113,436			97,216
Shares to cover employee payroll tax withholdings on stock issued under benefit plans	(339)	(3)	(19,283)						(19,286)
Tax benefits associated with stock-based compensation plans			6,464						6,464
Purchases of treasury stock	(15,378)					(835,001)			(835,001)
Other								2,068	2,068
<b>Balance, June 30, 2011</b>	158,212	\$ 2,146	\$2,317,074	\$3,945,037	\$ 34,043	\$(2,869,150)	\$	21,446	\$ 3,450,596

**Quest Diagnostics Stockholders' Equity**

	Shares of Common Stock Outstand- -ing	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Compre- -hensive Loss	Treasury Stock, at Cost	Compre- -hensive Income	Non- -controlling Interests	Total Stock- -holders' Equity
<b>Balance, December 31, 2009</b>	183,293	\$ 2,141	\$2,302,368	\$3,216,639	\$(20,961)	\$(1,510,548)	\$	21,825	\$ 4,011,464
Net income				357,063			\$357,063	17,966	375,029
Currency translation					(33,186)		(33,186)		(33,186)
Market valuation, net of tax expense of \$3,552					5,555		5,555		5,555
Net deferred loss on cash flow hedges					362		362		362
Comprehensive income							\$329,794		
Dividends declared				(35,844)					(35,844)
Distributions to noncontrolling interests								(16,830)	(16,830)
Issuance of common stock under benefit plans	869	2	(24,377)			34,618			10,243
Stock-based compensation expense			26,768			1,807			28,575
Exercise of stock options	1,027		(11,081)			51,255			40,174
Shares to cover employee payroll tax withholdings on stock issued under benefit plans	(271)	(1)	(5,489)			(9,614)			(15,104)
Tax benefits associated with stock-based compensation plans			2,628						2,628
Purchases of treasury stock	(7,741)					(425,773)			(425,773)
Other								(405)	(405)
<b>Balance, June 30, 2010</b>	177,177	\$ 2,142	\$2,290,817	\$3,537,858	\$(48,230)	\$(1,858,255)	\$	22,556	\$ 3,946,888

The accompanying notes are an integral part of these statements.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(dollars in thousands unless otherwise indicated)

**1. DESCRIPTION OF BUSINESS**

*Background*

Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") is the world's leading provider of diagnostic testing, information and services, providing insights that enable patients, physicians and others to make better healthcare decisions. Quest Diagnostics offers patients and physicians the broadest access to diagnostic laboratory services through the Company's nationwide network of laboratories and patient service centers. The Company provides interpretive consultation through the largest medical and scientific staff in the industry, with approximately 900 M.D.s and Ph.D.s, primarily located in the United States. Quest Diagnostics is the leading provider of clinical testing, including gene-based and esoteric testing, anatomic pathology services and testing for drugs-of-abuse in the United States, and the leading provider of risk assessment services for the life insurance industry in North America. The Company is also a leading provider of testing for clinical trials. The Company's diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. Quest Diagnostics empowers healthcare organizations and clinicians with robust information technology solutions that can improve patient care and medical practice.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Basis of Presentation*

The interim consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of financial condition, results of operations, and cash flows for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. The interim consolidated financial statements have been compiled without audit. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's 2010 Annual Report on Form 10-K.

The year-end balance sheet data was derived from the audited financial statements as of December 31, 2010, but does not include all the disclosures required by accounting principles generally accepted in the United States ("GAAP").

*Use of Estimates*

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

*Earnings Per Share*

The Company's unvested restricted common stock and unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.



**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
**(dollars in thousands unless otherwise indicated)**

*Adoption of New Accounting Standards*

On January 1, 2011, the Company adopted revised guidance issued by the Financial Accounting Standards Board ("FASB") related to the accounting for revenue in certain revenue arrangements that include software elements and in arrangements with multiple deliverables. The adoption of these standards did not have a material impact on the Company's consolidated financial statements.

On January 1, 2011, the Company adopted a new accounting standard related to the disclosures about the Company's use of fair value measurements relating to the tabular reconciliation of beginning and ending balances of the Level 3 (fair value determined based on significant unobservable inputs) classification and that provides greater disaggregation for each class of assets and liabilities that use fair value measurements. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

On January 1, 2011, the Company adopted a new accounting standard related to the accounting for insurance claims and related insurance recoveries. This standard clarifies that a healthcare entity may not net insurance recoveries against related professional claim liabilities in its balance sheet and also requires that claim liabilities shall be determined without consideration of insurance recoveries. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

On January 1, 2011, the Company adopted a new accounting standard pertaining to disclosures of charity care provided by healthcare entities. Under this new standard, the measurement basis for charity care disclosures is the cost of performing the services. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

On January 1, 2011, the Company adopted a new accounting standard related to goodwill which (1) modifies step one of the goodwill impairment test by requiring entities with reporting units that have a zero or negative carrying value to assess whether it is more likely than not that a goodwill impairment exists and (2) does not prescribe a specific method of calculating the carrying value of a reporting unit in the performance of step one of the goodwill impairment test. Under the requirements of this standard, if the entity concludes that it is more likely than not that an impairment of goodwill exists, the entity must perform step two of the goodwill impairment test. In determining whether it is more likely than not that an impairment of goodwill exists, an entity should consider whether there are any adverse qualitative factors indicating that an impairment exists. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

*New Accounting Standards*

In May 2011, the FASB issued an amendment to the accounting standards related to fair value measurements and disclosure requirements that result in a consistent definition of fair value and common requirements for the measurement and disclosure of fair value between GAAP and International Financial Reporting Standards. This standard provides certain amendments to the existing guidance on the use and application of fair value measurements and maintains a definition of fair value that is based on the notion of exit price. This standard will become effective for the Company on January 1, 2012 and is not expected to have a material impact on the Company's consolidated financial statements.

In June 2011, the FASB issued an amendment to the accounting standards related to the presentation of comprehensive income. This standard revises the manner in which entities present comprehensive income in their financial statements and removes the option to present items of other comprehensive income in the statement of changes in equity. This standard requires an entity to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements of net income and other comprehensive income. This standard will become effective retrospectively for the Company on January 1, 2012.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

**3. EARNINGS PER SHARE**

The computation of basic and diluted earnings per common share was as follows (in thousands, except per share data):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2011	2010	2011	2010
<b>Amounts attributable to Quest Diagnostics' stockholders:</b>				
Income from continuing operations	\$ 163,650	\$ 194,881	\$ 110,163	\$ 357,381
Loss from discontinued operations, net of taxes	(507)	(266)	(881)	(318)
Net income attributable to Quest Diagnostics' common stockholders	<u>\$ 163,143</u>	<u>\$ 194,615</u>	<u>\$ 109,282</u>	<u>\$ 357,063</u>
Income from continuing operations	\$ 163,650	\$ 194,881	\$ 110,163	\$ 357,381
Less: Earnings allocated to participating securities	877	928	967	1,588
Earnings available to Quest Diagnostics' common stockholders – basic and diluted	<u>\$ 162,773</u>	<u>\$ 193,953</u>	<u>\$ 109,196</u>	<u>\$ 355,793</u>
Weighted average common shares outstanding – basic	157,607	178,920	159,548	179,570
Effect of dilutive securities:				
Stock options and performance share units	1,745	1,840	1,730	2,002
Weighted average common shares outstanding – diluted	<u>159,352</u>	<u>180,760</u>	<u>161,278</u>	<u>181,572</u>
<b>Earnings per share attributable to Quest Diagnostics' common stockholders – basic:</b>				
Income from continuing operations	\$ 1.03	\$ 1.08	\$ 0.68	\$ 1.98
Loss from discontinued operations	—	—	—	—
Net income	<u>\$ 1.03</u>	<u>\$ 1.08</u>	<u>\$ 0.68</u>	<u>\$ 1.98</u>
<b>Earnings per share attributable to Quest Diagnostics' common stockholders – diluted:</b>				
Income from continuing operations	\$ 1.02	\$ 1.07	\$ 0.68	\$ 1.96
Loss from discontinued operations	—	—	(0.01)	—
Net income	<u>\$ 1.02</u>	<u>\$ 1.07</u>	<u>\$ 0.67</u>	<u>\$ 1.96</u>

Stock options and performance share units of 2.3 million shares and 2.2 million shares for the three and six months ended June 30, 2011, respectively, were not included due to their antidilutive effect.

Stock options and performance share units of 3.1 million shares and 2.9 million shares for the three and six months ended June 30, 2010, respectively, were not included due to their antidilutive effect.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

**4. BUSINESS ACQUISITIONS**

*Acquisition of Athena Diagnostics*

On April 4, 2011, the Company completed its acquisition of Athena Diagnostics ("Athena") from Thermo Fisher Scientific, Inc., in an all-cash transaction valued at \$740 million. Athena is the leading provider of advanced diagnostic tests related to neurological conditions, and generated revenues of approximately \$110 million in 2010.

Through the acquisition, the Company acquired all of Athena's operations. The Company financed the all-cash purchase price of \$740 million and related transaction costs with a portion of the net proceeds from the Company's 2011 Senior Notes Offering. For the three and six months ended June 30, 2011, transaction costs of \$7.1 million and \$8.2 million, respectively, were recorded in selling, general and administrative expenses. See Note 8 for further discussion of the 2011 Senior Notes Offering.

The acquisition of Athena was accounted for under the acquisition method of accounting. As such, the cost to acquire Athena was allocated to the respective assets acquired and liabilities assumed based on their estimated fair values as of the closing date. A preliminary allocation of the cost to acquire Athena has been made to certain assets and liabilities of Athena based on preliminary estimates. The Company is continuing to assess the estimated fair values of certain assets acquired and liabilities assumed. The consolidated financial statements include the results of operations of Athena subsequent to the closing of the acquisition which are not material to the Company's consolidated results of operations.

The following table summarizes the Company's preliminary purchase price allocation of the cost to acquire Athena:

		<b>Preliminary Fair Values as of April 4, 2011</b>
Cash and cash equivalents	\$	—
Accounts receivable		17,853
Other current assets		13,427
Property, plant and equipment		3,038
Intangible assets		220,040
Goodwill		563,974
Other assets		135
Total assets acquired		818,467
Current liabilities		8,511
Non-current deferred income taxes		69,956
Total liabilities assumed		78,467
Net assets acquired	\$	740,000

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

The acquired amortizable intangible assets are being amortized over their estimated useful lives as follows:

	<b>Preliminary Fair Values</b>	<b>Weighted Average Useful Life</b>
Technology	\$ 92,580	16 years
Non-compete agreement	37,000	4 years
Tradename	34,520	10 years
Customer relationships	21,420	20 years
Informatics database	34,520	10 years
	<u>\$ 220,040</u>	

Of the amount allocated to goodwill and intangible assets, approximately \$42 million is expected to be deductible for tax purposes. All of the goodwill acquired in connection with the Athena acquisition has been allocated to the Company's clinical testing business. As of the acquisition date, the fair value of accounts receivable approximated its book value, all of which is expected to be collected.

*Acquisition of Celera Corporation*

On March 17, 2011, the Company entered into a definitive merger agreement with Celera Corporation ("Celera") under which the Company agreed to acquire Celera in a transaction valued at approximately \$341 million, net of \$326 million in acquired cash and short-term marketable securities. Additionally, the Company expects to utilize Celera's available tax credits, net operating loss carryforwards and capitalized tax research and development expenditures to reduce its future tax payments by approximately \$110 million. Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Celera generated revenues of \$128 million in 2010.

Under the terms of the definitive merger agreement, the Company, through a wholly-owned subsidiary, commenced a cash tender offer to purchase all of the outstanding shares of common stock of Celera for \$8 per share in cash. On May 4, 2011, the Company announced that as a result of the tender offer, the Company had a controlling ownership interest in Celera. On May 17, 2011, the Company completed the acquisition by means of a short-form merger, in which the remaining shares of Celera common stock that had not been tendered into the tender offer were converted into the right to receive \$8 per share in cash. The Company has accounted for the acquisition of Celera as a single transaction, effective May 4, 2011.

Through the acquisition, the Company acquired all of Celera's operations. The Company financed the all-cash purchase price of \$667 million and related transaction costs with borrowings under its existing credit facilities and cash on hand. Of the total cash purchase price of \$667 million, \$508 million was paid through June 30, 2011. Accounts payable and accrued expenses at June 30, 2011 included a liability of \$159 million representing the remaining merger consideration related to shares of Celera which had not been surrendered as of June 30, 2011. The Company expects to fund the payment of the remaining merger consideration with cash on hand and its existing credit facilities.

For the three and six months ended June 30, 2011, transaction costs of \$7.2 million and \$8.4 million, respectively, were recorded in selling, general and administrative expenses. Additionally, for the three and six months ended June 30, 2011, financing related costs of \$0.8 million and \$3.1 million, respectively, were recorded in interest expense, net.

The acquisition of Celera was accounted for under the acquisition method of accounting. As such, the cost to acquire Celera was allocated to the respective assets acquired and liabilities assumed based on their estimated fair values as of the date the Company acquired its controlling ownership interest in Celera. A preliminary allocation of the cost to

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

acquire Celera has been made to certain assets and liabilities of Celera based on preliminary estimates. The Company is continuing to assess the estimated fair values of certain assets acquired and liabilities assumed. The consolidated financial statements include the results of operations of Celera subsequent to the Company acquiring its controlling ownership interest which are not material to the Company's consolidated results of operations.

The following table summarizes the Company's preliminary purchase price allocation of the cost to acquire Celera:

		<b>Preliminary Fair Values as of May 4, 2011</b>
Cash and cash equivalents	\$	112,312
Short-term marketable securities		213,418
Accounts receivable		16,810
Other current assets		25,809
Property, plant and equipment		11,091
Intangible assets		85,830
Goodwill		134,283
Non-current deferred income taxes		102,838
Other assets		34,586
<b>Total assets acquired</b>		<b>736,977</b>
<b>Current liabilities</b>		<b>59,008</b>
<b>Long-term liabilities</b>		<b>10,717</b>
<b>Total liabilities assumed</b>		<b>69,725</b>
<b>Net assets acquired</b>	<b>\$</b>	<b>667,252</b>

The acquired amortizable intangible assets are being amortized over their estimated useful lives as follows:

	<b>Preliminary Fair Values</b>	<b>Weighted Average Useful Life</b>
Outlicensed technology	\$ 46,450	6 years
Technology	21,730	8 years
Customer relationships	6,750	9 years
Tradename	5,400	5 years
	<b>\$ 80,330</b>	

In addition to the amortizable intangible assets noted above, \$5.5 million was allocated to in-process research and development, which is currently not subject to amortization.

Of the amount allocated to goodwill and intangible assets, approximately \$28 million is expected to be deductible for tax purposes. Of the total goodwill acquired in connection with the Celera acquisition, approximately \$103 million has been allocated to the Company's clinical testing business, with the remainder allocated to the Company's diagnostics products business. As of the acquisition date, the fair value of accounts receivable approximated its book value, all of which is expected to be collected.

Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the Athena and Celera acquisitions includes: the

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

expected synergies resulting from combining the operations of the acquired businesses with those of the Company; and the value associated with an assembled workforce that has a historical track record of identifying opportunities, developing services and products, and commercializing them.

*Pro Forma Combined Financial Information*

Supplemental pro forma combined financial information has not been presented as the combined impact of the Athena and Celera acquisitions is not material to the Company's consolidated financial statements.

**5. FAIR VALUE MEASUREMENTS**

The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:

	<b>Basis of Fair Value Measurements</b>		
	<b>Quoted Prices in Active Markets for Identical Assets / Liabilities</b>	<b>Significant Other Observable Inputs</b>	<b>Significant Unobservable Inputs</b>
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
<b>June 30, 2011</b>			
<b>Assets:</b>			
Trading securities	\$ 47,830	\$ 47,830	\$ —
Interest rate swaps	18,939	—	18,939
Cash surrender value of life insurance policies	21,968	—	21,968
Available-for-sale equity securities	2,451	—	2,451
Foreign currency forward contracts	1,094	—	1,094
<b>Total</b>	<b>\$ 92,282</b>	<b>\$ 47,830</b>	<b>\$ 2,451</b>
<b>Liabilities:</b>			
Deferred compensation liabilities	\$ 73,124	\$ —	\$ 73,124
Foreign currency forward contracts	110	—	110
<b>Total</b>	<b>\$ 73,234</b>	<b>\$ —</b>	<b>\$ 73,234</b>

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

**Basis of Fair Value Measurements**

	Basis of Fair Value Measurements		
	Quoted Prices in Active Markets for Identical Assets / Liabilities	Significant Other Observable Inputs	Significant Unobservable Inputs
	Level 1	Level 2	Level 3
<b>December 31, 2010</b>			
<b>Assets:</b>			
Trading securities	\$ 38,740	\$ 38,740	\$ —
Cash surrender value of life insurance policies	20,314	—	20,314
Interest rate swaps	10,483	—	10,483
Available-for-sale equity securities	5,066	—	5,066
Foreign currency forward contracts	4,527	—	—
<b>Total</b>	<b>\$ 79,130</b>	<b>\$ 38,740</b>	<b>\$ 35,324</b>
<b>Liabilities:</b>			
Deferred compensation liabilities	\$ 61,964	\$ —	\$ 61,964
Foreign currency forward contracts	464	—	464
<b>Total</b>	<b>\$ 62,428</b>	<b>\$ —</b>	<b>\$ 62,428</b>

The Company offers certain employees the opportunity to participate in supplemental deferred compensation plans. A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities. Changes in the fair value of these securities are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held exclusive of any transaction costs. A corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation. The deferred compensation liabilities are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the trading securities.

The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program. A participant's deferrals, together with Company matching credits, are "invested" at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the deferred compensation obligations are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments.

The fair value measurements of foreign currency forward contracts are obtained from a third-party pricing service and are based on market prices in actual transactions and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The fair value measurements of the Company's interest rate swaps are model-derived valuations as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present and future market conditions. The Company does not believe that the changes in the fair values of its foreign currency forward contracts and interest rate swaps will materially differ from the amounts that could be realized upon settlement or maturity or that the changes in fair value will have a material effect on its results of operations, liquidity and capital resources.

Investments in available-for-sale equity securities consist of the revaluation of an existing investment in unregistered common shares of a publicly-held company. This investment is classified within Level 3 because the

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

unregistered securities contain restrictions on their sale, and therefore, the fair value measurement reflects a discount for the effect of the restriction.

The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. At June 30, 2011 and December 31, 2010, the fair value of the Company's debt was estimated at \$4.6 billion and \$3.1 billion, respectively, using quoted market prices and yields for the same or similar types of borrowings, taking into account the underlying terms of the debt instruments. At June 30, 2011 and December 31, 2010, the estimated fair value exceeded the carrying value of the debt by \$228 million and \$80 million, respectively.

**6. TAXES ON INCOME**

Income tax expense for the six months ended June 30, 2011 and 2010 was \$155 million and \$231 million, respectively. The increase in the effective income tax rate for the six months ended June 30, 2011 is primarily due to a charge recorded in the first quarter of 2011 associated with a settlement of certain legal claims (see Note 12), a portion for which a tax benefit has not been recorded.

**7. GOODWILL AND INTANGIBLE ASSETS**

The changes in goodwill for the six months ended June 30, 2011 and for the year ended December 31, 2010 are as follows:

	<b>June 30, 2011</b>	<b>December 31, 2010</b>
Balance at beginning of period	\$ 5,101,938	\$ 5,083,944
Goodwill acquired during the year	698,257	—
Other purchase accounting adjustments	—	246
Increase related to foreign currency translation	16,774	17,748
<b>Balance at end of period</b>	<b>\$ 5,816,969</b>	<b>\$ 5,101,938</b>

Approximately 90% of the Company's goodwill as of June 30, 2011 and December 31, 2010 was associated with its clinical testing business.

For the six months ended June 30, 2011, goodwill acquired was associated with the Athena and Celera acquisitions (see Note 4 for further details).

For the year ended December 31, 2010, other purchase accounting adjustments were primarily related to a milestone payment on an acquisition from 2008.



**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

Intangible assets at June 30, 2011 and December 31, 2010 consisted of the following:

	Weighted Average Amortization Period	June 30, 2011			December 31, 2010		
		Cost	Accumulated Amortization	Net	Cost	Accumulated Amortization	Net
<b>Amortizing intangible assets:</b>							
Customer-related intangibles	19 years	\$ 633,733	\$ (177,693)	\$ 456,040	\$ 603,203	\$ (161,345)	\$ 441,858
Non-compete agreements	4 years	91,897	(55,387)	36,510	54,886	(52,134)	2,752
Technology	14 years	168,575	(22,005)	146,570	51,830	(16,796)	35,034
Other	8 years	146,331	(14,237)	132,094	24,065	(9,380)	14,685
<b>Total</b>	<b>16 years</b>	<b>1,040,536</b>	<b>(269,322)</b>	<b>771,214</b>	<b>733,984</b>	<b>(239,655)</b>	<b>494,329</b>
<b>Intangible assets not subject to amortization:</b>							
In-process research and development		5,500	—	5,500	—	—	—
Tradenames		305,457	—	305,457	302,076	—	302,076
<b>Total intangible assets</b>		<b>\$ 1,351,493</b>	<b>\$ (269,322)</b>	<b>\$ 1,082,171</b>	<b>\$ 1,036,060</b>	<b>\$ (239,655)</b>	<b>\$ 796,405</b>

The increase in intangible assets for the six months ended June 30, 2011 was primarily due to intangible assets acquired as part of the Athena and Celera acquisitions (see Note 4 for further details).

Amortization expense related to intangible assets was \$18.6 million and \$9.3 million for the three months ended June 30, 2011 and 2010, respectively. For the six months ended June 30, 2011 and 2010, amortization expense related to intangible assets was \$28.4 million and \$18.6 million, respectively.

The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of June 30, 2011 is as follows:

**Fiscal Year Ending December 31,**

Remainder of 2011	\$	38,451
2012		77,424
2013		75,530
2014		73,789
2015		63,328
2016		56,629
Thereafter		386,063
<b>Total</b>	<b>\$</b>	<b>771,214</b>

**8. DEBT**

Short-term borrowings and current portion of long-term debt at June 30, 2011 and December 31, 2010 consisted of the following:

	June 30, 2011	December 31, 2010
Borrowings under Secured Receivables Credit Facility	\$ 85,000	\$ —
Current portion of long-term debt	909,675	348,996
<b>Total short-term borrowings and current portion of long-term debt</b>	<b>\$ 994,675</b>	<b>\$ 348,996</b>

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

Long-term debt at June 30, 2011 and December 31, 2010 consisted of the following:

	June 30, 2011	December 31, 2010
Senior Notes due July 2011	\$ 159,266	\$ 159,234
Term Loan due May 2012	742,000	742,000
Floating Rate Senior Notes due March 2014	200,000	—
Senior Notes due November 2015	499,307	499,227
Senior Notes due April 2016	303,153	—
Senior Notes due July 2017	374,521	374,480
Senior Notes due January 2020	509,179	503,770
Senior Notes due April 2021	549,106	—
Senior Notes due July 2037	420,918	420,840
Senior Notes due January 2040	438,114	243,422
Other	47,042	47,183
Total long-term debt	4,242,606	2,990,156
Less: current portion of long-term debt	909,675	348,996
Total long-term debt, net of current portion	\$ 3,332,931	\$ 2,641,160

*2011 Senior Notes Offering*

On March 24, 2011, the Company completed a \$1.25 billion senior notes offering (the "2011 Senior Notes"). The 2011 Senior Notes were sold in four tranches: (a) \$200 million aggregate principal amount of three-month LIBOR plus 0.85% floating rate senior notes due March 24, 2014 (the "Floating Rate Senior Notes due 2014"), issued at par, (b) \$300 million aggregate principal amount of 3.20% senior notes due April 1, 2016 (the "Senior Notes due 2016"), issued at a discount of \$0.3 million, (c) \$550 million aggregate principal amount of 4.70% senior notes due April 1, 2021 (the "Senior Notes due 2021"), issued at a discount of \$0.9 million and (d) \$200 million aggregate principal amount of 5.75% senior notes due January 30, 2040 (the "Senior Notes due 2040"), issued at a discount of \$5.5 million. The Senior Notes due 2040 are a reopening of the \$250 million aggregate principal amount of 5.75% Senior Notes due 2040 issued on November 17, 2009. After considering the discounts, the effective interest rates on the Senior Notes due 2016, the Senior Notes due 2021 and the Senior Notes due 2040 are 3.22%, 4.72% and 5.95%, respectively. The Floating Rate Senior Notes due 2014 require quarterly interest payments, which commenced on June 24, 2011. The three-month LIBOR was 0.25% at June 30, 2011. The Senior Notes due 2016 and the Senior Notes due 2021 require semi-annual interest payments, which commence on October 1, 2011. The Senior Notes due 2040 require semi-annual interest payments, which commence on July 30, 2011. The 2011 Senior Notes are unsecured obligations of the Company and rank equally with the Company's other unsecured obligations. The 2011 Senior Notes do not have a sinking fund requirement and are guaranteed by certain of the Company's domestic, wholly-owned subsidiaries (the "Subsidiary Guarantors").

The Company incurred \$10.4 million of costs associated with the 2011 Senior Notes, which is being amortized over the term of the related debt.

The Company used \$750 million of the net proceeds from the 2011 Senior Notes to fund the purchase price and related transaction costs associated with its acquisition of Athena, which closed on April 4, 2011 (See Note 4), and \$485 million of the net proceeds, together with \$90 million of cash on hand, to repay outstanding indebtedness under the Company's senior unsecured revolving credit facility and its secured receivables credit facility.

As further discussed in Note 9, the Company has hedged its interest rate exposure on a portion of the Senior Notes due 2016 and on a portion of the Senior Notes due 2020 which have been designated as fair value hedges. The carrying value of the Senior Notes due 2016 has been increased by the fair value of the related hedge of \$3.4 million in the consolidated balance sheet as of June 30, 2011. At June 30, 2011 and December 31, 2010, the carrying value of the Senior Notes due 2020 has been increased by the fair value of the related hedge of \$15.5 million and \$10.5 million, respectively.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

As of June 30, 2011, long-term debt matures as follows:

**Fiscal Year Ending December 31,**

Remainder of 2011	\$	345,432
2012		568,175
2013		7,766
2014		207,365
2015		504,814
2016		300,779
Thereafter		2,313,980
Total maturities of debt		4,248,311
Unamortized discount		(24,644)
Fair value basis adjustment attributable to hedged debt		18,939
Total debt		4,242,606
Current portion of long-term debt		(909,675)
Total long-term debt, net of current portion	\$	3,332,931

A full description of the terms of the Company's indebtedness and related service requirements is contained in Note 10 to the Consolidated Financial Statements in the Company's 2010 Annual Report on Form 10-K.

**9. FINANCIAL INSTRUMENTS**

The Company uses derivative financial instruments to manage its exposure to market risks for changes in interest rates and foreign currencies. This strategy includes the use of interest rate swap agreements, forward starting interest rate swap agreements, treasury lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative or trading purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral.

A summary of the fair values of derivative instruments in the consolidated balance sheets is stated in the table below:

	June 30, 2011		December 31, 2010	
	Balance Sheet Classification	Fair Value	Balance Sheet Classification	Fair Value
<b>Derivatives Designated as Hedging Instruments</b>				
Asset Derivatives:				
Interest rate swaps	Other assets	\$ 18,939	Other assets	\$ 10,483
<b>Derivatives Not Designated as Hedging Instruments</b>				
Asset Derivatives:				
Foreign currency forward contracts	Other current assets	\$ 1,094	Other current assets	\$ 4,527
Liability Derivatives:				
Foreign currency forward contracts	Other current liabilities	\$ 110	Other current liabilities	\$ 464
<b>Total Net Derivatives Asset</b>		<b>\$ 19,923</b>		<b>\$ 14,546</b>

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
**(dollars in thousands unless otherwise indicated)**

*Interest Rate Risk*

The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has entered into interest rate swaps. Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense.

The Company formally documents its hedge relationships, including identifying the hedging instruments and the hedged items, as well as its risk management objectives and strategies for undertaking the hedge transaction. On the date the derivative is entered into, the Company designates the type of derivative as a fair value hedge or cash flow hedge, and accounts for the derivative in accordance with its designation as prescribed by the standards on accounting for derivative instruments and hedging activities. At inception and at least quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness.

The Company accounts for its derivatives as either an asset or liability measured at its fair value. The fair value is based upon quoted market prices obtained from third-party financial institutions and includes an adjustment for the credit risk of the obligor's non-performance. For a derivative instrument that has been formally designated as a fair value hedge, fair value gains or losses on the derivative instrument are reported in earnings, together with offsetting fair value gains or losses on the hedged item that are attributable to the risk being hedged. For derivatives that have been formally designated as a cash flow hedge, the effective portion of changes in the fair value of the derivatives is recorded in accumulated other comprehensive income and the ineffective portion is recorded in earnings. Upon maturity or early termination of an effective interest rate swap designated as a cash flow hedge, unrealized gains or losses are deferred in stockholders' equity, as a component of accumulated other comprehensive income, and are amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings. If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive income, unless it is probable that the forecasted transaction will not occur. If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting, and any deferred gains or losses reported in accumulated other comprehensive income are classified into earnings immediately.

*Interest Rate Derivatives – Cash Flow Hedges*

In March 2011, the Company entered into interest rate lock agreements with several financial institutions for a total notional amount of \$400 million (the "Treasury Lock Agreements"). The Treasury Lock Agreements, which had an original maturity date of April 5, 2011, were entered into to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in the 10-year and 30-year U.S. treasury rates related to the planned issuance of debt securities. In connection with the Company's senior notes offering in March 2011 (see Note 8), the Company paid \$3.1 million to settle the Treasury Lock Agreements which have been accounted for as cash flow hedges. These losses are deferred in stockholders' equity, as a component of accumulated other comprehensive income, and are amortized as an adjustment to interest expense over the term of the Senior Notes due 2021 and Senior Notes due 2040.

In previous years, the Company entered into various forward starting interest rate swap agreements and treasury-lock agreements that were accounted for as cash flow hedges (see Note 11 to the Consolidated Financial Statements in the Company's 2010 Annual Report on Form 10-K for further details). The effective portions of the changes in fair value of these derivatives represent deferred gains or losses that are recorded in accumulated other comprehensive income. These deferred gains or losses are reclassified from accumulated other comprehensive income to the statement of operations in the same period or periods during which the hedged transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows. The total loss, net of tax benefit, recognized in accumulated other

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
**(dollars in thousands unless otherwise indicated)**

comprehensive income on the cash flow hedges as of June 30, 2011 and December 31, 2010 was \$8.1 million and \$6.6 million, respectively. The loss recognized on the Company's cash flow hedges for the three and six months ended June 30, 2011 and 2010, as a result of ineffectiveness, was not material. The net amount of deferred losses on cash flow hedges that is expected to be reclassified from accumulated other comprehensive income into earnings within the next 12 months is \$1.3 million.

*Interest Rate Derivatives – Fair Value Hedges*

In March 2011, the Company entered into various fixed-to-variable interest rate swap agreements (the "2011 Fixed-to-Variable Interest Rate Swap Agreements") which have an aggregate notional amount of \$200 million and a variable interest rate based on six-month LIBOR plus 0.54%.

In November 2009, the Company entered into various fixed-to-variable interest rate swap agreements (the "2009 Fixed-to-Variable Interest Rate Swap Agreements") which have an aggregate notional amount of \$350 million and a variable interest rate based on one-month LIBOR plus 1.33%.

These derivative financial instruments are accounted for as fair value hedges of a portion of the Senior Notes due 2016 and a portion of the Senior Notes due 2020 and effectively convert that portion of the debt into variable interest rate debt. The Company recognizes the changes in the fair value of both the fixed-to-variable interest rate swap agreements and the related underlying debt obligations in other (expense) income, net as equal and offsetting gains and losses. The fair value of the 2011 Fixed-to-Variable Interest Rate Swap Agreements was an asset of \$3.4 million at June 30, 2011. At June 30, 2011 and December 31, 2010, the fair value of the 2009 Fixed-to-Variable Interest Rate Swap Agreements was an asset of \$15.5 million and \$10.5 million, respectively. Since inception, the fair value hedges have been effective; therefore, there is no impact on earnings for the three and six months ended June 30, 2011 and 2010 as a result of hedge ineffectiveness.

*Foreign Currency Risk*

The Company is exposed to market risk for changes in foreign exchange rates primarily under certain intercompany receivables and payables. Foreign exchange forward contracts are used to mitigate the exposure of the eventual net cash inflows or outflows resulting from these intercompany transactions. The objective is to hedge a portion of the forecasted foreign currency risk over a rolling 12-month time horizon to mitigate the eventual impacts of changes in foreign exchange rates on the cash flows of the intercompany transactions. As of June 30, 2011, the gross notional amount of foreign currency forward contracts in U.S. dollars was \$55.4 million and principally consists of contracts in Swedish krona and British pounds. The Company does not designate these derivative instruments as hedges under current accounting standards unless the benefits of doing so are material. The Company's foreign exchange exposure is not material to the Company's consolidated financial condition or results of operations. The Company does not hedge its net investment in non-U.S. subsidiaries because it views those investments as long-term in nature.

**10. STOCKHOLDERS' EQUITY**

*Components of Comprehensive Income*

The market valuation adjustment for the six months ended June 30, 2011 and 2010 represents unrealized holding (losses) gains on available-for-sale securities, net of taxes. The net deferred loss on cash flow hedges for the six months ended June 30, 2011 and 2010 represents deferred losses on the Company's interest rate related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 9). Foreign currency translation adjustments are not adjusted for income taxes since they relate to indefinite investments in non-U.S. subsidiaries.

*Comprehensive Income*

For the three months ended June 30, 2011 and 2010, comprehensive income was \$165 million and \$169 million, respectively.

*Dividend Program*

During each of the quarters of 2011 and 2010, the Company's Board of Directors has declared a quarterly cash dividend of \$0.10 per common share.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

*Share Repurchase Plan*

In January 2011, the Company's Board of Directors authorized the Company to repurchase an additional \$750 million of the Company's common stock, increasing the total available authorization at that time to \$1 billion. The share repurchase authorization has no set expiration or termination date.

For the six months ended June 30, 2011, the Company repurchased 15.4 million shares of its common stock from SB Holdings Capital Inc., a wholly-owned subsidiary of GlaxoSmithKline plc., at an average price of \$54.30 per share for a total of \$835 million. For the three and six months ended June 30, 2011, the Company reissued 1.1 million shares and 2.4 million shares, respectively, for employee benefit plans. At June 30, 2011, \$165 million remained available under the Company's share repurchase authorizations.

For the three months ended June 30, 2010, the Company repurchased 3.3 million shares of its common stock at an average price of \$53.36 per share for a total of \$175 million. For the six months ended June 30, 2010, the Company repurchased 7.7 million shares of its common stock at an average price of \$55.00 per share for \$426 million, including 4.5 million shares purchased in the first quarter at an average price per share of \$56.21 for \$251 million under an accelerated share repurchase transaction ("ASR") with a bank.

Under the ASR, in January 2010, the Company repurchased 4.5 million shares of the Company's outstanding common stock for an initial purchase price of \$56.05 per share. The purchase price of these shares was subject to an adjustment based on the volume weighted average price of the Company's common stock during a period following execution of the agreement. The total cost of the initial purchase was \$250 million. The purchase price adjustment was settled in the first quarter of 2010 and resulted in an additional cash payment of \$0.7 million, for a final purchase price of \$251 million, or \$56.21 per share.

For the three and six months ended June 30, 2010, the Company reissued 0.6 million shares and 1.6 million shares, respectively, for employee benefit plans.

**11. SUPPLEMENTAL CASH FLOW & OTHER DATA**

	Three Months Ended June 30,		Six Months Ended June 30,	
	2011	2010	2011	2010
Depreciation expense	\$ 54,127	\$ 53,704	\$ 107,643	\$ 107,678
Interest expense	(47,231)	(36,640)	(85,510)	(73,170)
Interest income	650	273	1,000	848
Interest expense, net	(46,581)	(36,367)	(84,510)	(72,322)
Interest paid	17,539	21,103	72,583	56,415
Income taxes paid	97,119	190,289	107,721	197,118
Assets acquired under capital leases	1,876	—	2,697	—
<u>Businesses acquired:</u>				
Fair value of assets acquired	1,555,444	—	1,555,444	—
Fair value of liabilities assumed	148,192	—	148,192	—
Fair value of net assets acquired	1,407,252	—	1,407,252	—
Less: Merger consideration payable	158,560	—	158,560	—
Cash paid for business acquisitions	1,248,692	—	1,248,692	—
Less: Cash acquired	112,312	—	112,312	—
Business acquisitions, net of cash acquired	\$ 1,136,380	\$ —	\$ 1,136,380	\$ —

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
**(dollars in thousands unless otherwise indicated)**

**12. COMMITMENTS AND CONTINGENCIES**

The Company has a line of credit with a financial institution totaling \$85 million for the issuance of letters of credit (the "Letter of Credit Line"). The Letter of Credit Line, which is renewed annually, matures on November 19, 2011 and is guaranteed by the Subsidiary Guarantors.

In support of its risk management program, to ensure the Company's performance or payment to third parties, \$63 million in letters of credit were outstanding at June 30, 2011. The letters of credit primarily represent collateral for current and future automobile liability and workers' compensation loss payments. In addition, \$6 million of bank guarantees were outstanding at June 30, 2011 in support of certain foreign operations.

*Contingent Lease Obligations*

The Company is subject to contingent obligations under certain leases and other instruments incurred in connection with real estate activities and other operations associated with LabOne, Inc., which the Company acquired in 2005, and certain of its predecessor companies. No liability has been recorded for any of these potential contingent obligations. See Note 15 to the Consolidated Financial Statements contained in the Company's 2010 Annual Report on Form 10-K for further details.

*Legal Matters*

The Company is involved in various legal proceedings. Some of the proceedings against the Company involve claims that are substantial in amount.

*California Lawsuit*

In 2006 and 2008, the Company and several of its subsidiaries received subpoenas from the California Attorney General's Office (the "Attorney General") seeking documents relating to the Company's billings to Medi-Cal, the California Medicaid program. The Company cooperated with the government's requests. Subsequently, the State of California intervened as plaintiff in a civil lawsuit, California ex rel. Hunter Laboratories, LLC v. Quest Diagnostics Incorporated., et al. (the "California Lawsuit"), filed in California Superior Court against a number of clinical laboratories, including the Company and several of its subsidiaries. The complaint was originally filed by a competitor laboratory in California under the whistleblower provisions of the California False Claims Act. The complaint was unsealed on March 20, 2009.

The plaintiffs alleged, among other things, that the Company overcharged Medi-Cal for testing services and violated the California False Claims Act. Specifically, the plaintiffs alleged, among other things, that the Company violated certain regulations that govern billing to Medi-Cal ("Comparable Charge" regulations). A liability finding could have lead to an injunction, fines or penalties, and exclusion from Medi-Cal, as well as claims by third parties.

In the third quarter of 2010, the California Department of Health Care Services (the "Department") conducted an audit of the Company's billing to Medi-Cal. The Department contended that the Company's billings were not consistent with applicable California regulations, as then interpreted by the Department. While the Company believes it was in compliance in all material respects with California requirements applicable to billing for clinical laboratory testing, the Company entered into an interim agreement under which it agreed to temporarily suspend billing Medi-Cal for a period of up to six months through March 1, 2011, during which it continued to provide services. The agreement was subsequently extended. The Company continued to recognize revenue from Medi-Cal for services provided in accordance with its interpretation of California regulations related to billing for clinical laboratory testing.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
**(dollars in thousands unless otherwise indicated)**

The Company engaged in discussions in an attempt to resolve the matters described above. Agreement with both the Attorney General and the Department was required to settle this matter. During the fourth quarter of 2010, the Company reached an understanding, which was highly conditioned, to settle these matters pursuant to which the Company would pay \$241 million. Conditions included, but were not limited to, reaching an agreement regarding the manner in which the Company's future billings would be treated by the Department. In subsequent discussions during the fourth quarter of 2010, the Attorney General and the Department rejected the Company's proposals that would have addressed these outstanding issues. As a result, as of the issuance of the Company's financial statements for 2010, settlement discussions had reached an impasse. Based on these facts and circumstances, the Company concluded that a liability was not probable as of December 31, 2010.

In the first quarter of 2011, settlement discussions resumed. On May 9, 2011, the Company announced an agreement in principle to resolve these matters. On May 19, 2011, the Company finalized a settlement and release with the Attorney General, the Department and the *qui tam* relator. While denying liability, in order to avoid the uncertainty, expense and risks of litigation, the Company agreed to resolve these matters for \$241 million. The Company agreed to the settlement to resolve the Comparable Charge allegations; the Company received a full release of these and all other allegations in the complaint. The Company also agreed to certain reporting obligations regarding its pricing for a limited time period and, at the option of the Company in lieu of such obligations for a transitional period, to provide Medi-Cal with a discount (the "Transitional Discount") until the end of July 2012. The Transitional Discount, to the extent provided, is not expected to have a material impact on the Company's consolidated revenues or results of operations.

As provided for in the settlement agreement, the Company resumed billing for unbilled services and expects to be reimbursed for all services provided prior to the effective date of the settlement agreement. Such reimbursement is expected to be consistent with the related amounts accrued.

As a result of the agreement in principle, the Company recorded a pre-tax charge to earnings in the first quarter of 2011 of \$236 million, which represented the cost to resolve the matters noted above and related claims, less amounts previously reserved for related matters. The Company funded the \$241 million payment in the second quarter of 2011 with cash on hand and borrowings under its existing credit facilities.

*Other Legal Matters*

In 2005, the Company received a subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General, seeking business records including records regarding the Company's relationship with health maintenance organizations, independent physician associations, group purchasing organizations, and preferred provider organizations relating back to 1995. The Company has cooperated with the investigation. Subsequently, in November 2009, the U.S. District Court for the Southern District of New York partially unsealed a civil complaint, U.S. ex rel. Fair Laboratory Practices Associates v. Quest Diagnostics Incorporated, filed against the Company under the whistleblower provisions of the federal False Claims Act. The complaint alleges, among other things, violations of the federal Anti-Kickback Statute and the federal False Claims Act in connection with the Company's pricing of laboratory services. The complaint seeks damages for alleged false claims associated with laboratory tests reimbursed by government payors, treble damages and civil penalties. In March 2011, the district court granted the Company's motion to dismiss the relators' complaint and disqualified the relators and their counsel from pursuing an action based on the facts alleged in the complaint; the relators filed a notice of appeal. The government was given additional time to decide whether to join the case. In July 2011, the government filed a notice declining to intervene in the action and the Court entered a final judgment in the Company's favor. The relators' appeal is pending.

In April 2010, a putative class action was filed against the Company and NID in the U.S. District Court for the Eastern District of New York on behalf of entities that allegedly purchased or paid for certain of NID's test kits. The complaint alleges that certain of NID's test kits were defective and that defendants, among other things, violated RICO and state consumer protection laws. The complaint alleges an unspecified amount of damages.

In August 2010, a shareholder derivative action was filed in the Superior Court of New Jersey, Morris County, on behalf of the Company against the directors and certain present officers of the Company. The complaint alleges that the defendants breached their fiduciary duties in connection with, among other things, alleged overcharges by the Company to Medi-Cal for testing services, and seeks unspecified compensatory damages and equitable relief. The action was dismissed without prejudice. On July 21, 2011, the action was re-filed.

In November 2010, a putative class action was filed against the Company and certain present and former officers of the Company in the Superior Court of New Jersey, Essex County, on behalf of the Company's sales people nationwide who were over forty years old and who either resigned or were terminated after being placed on a performance improvement plan. The complaint alleges that the defendants' conduct violates the New Jersey Law Against Discrimination, and seeks, among other things, unspecified damages. The defendants removed the complaint to the United States District Court for the District of New Jersey.



**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
**(dollars in thousands unless otherwise indicated)**

In June 2011, a shareholder derivative action was filed in the Superior Court of New Jersey, on behalf of the Company against the current directors and a former director of the Company. The complaint alleges that the defendants breached their fiduciary duties, wasted corporate assets and were unjustly enriched in connection with, among other things, alleged overcharges by the Company to Medi-Cal for testing services, and seeks unspecified compensatory damages and equitable relief.

In addition, the Company and certain of its subsidiaries have received subpoenas from state agencies in five states and from the Office of the Inspector General of the U.S. Department of Health and Human Services which seek documents relating to the Company's billing practices. The Company is cooperating with the requests.

The federal or state governments may bring claims based on new theories as to the Company's practices which management believes to be in compliance with law. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers. The Company is aware of certain pending individual or class action lawsuits, and has received several subpoenas, related to billing practices filed under the qui tam provisions of the Civil False Claims Act and/or other federal and state statutes, regulations or other laws. The Company understands that there may be other pending qui tam claims brought by former employees or other "whistle blowers" as to which the Company cannot determine the extent of any potential liability.

These matters are in different stages. Some of these matters are in their early stages. Matters may involve responding to and cooperating with various government investigations and related subpoenas. As of June 30, 2011, the Company does not believe that any losses related to these matters are probable. While the Company believes that a reasonable possibility exists that losses may have been incurred, based on the nature and status of the matters, potential losses, if any, cannot be estimated.

*Reserves for Legal Matters*

Management has established reserves in accordance with generally accepted accounting principles for the matters discussed above. Such reserves totaled approximately \$2 million and \$10 million as of June 30, 2011 and December 31, 2010, respectively. Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing accruals for loss estimates related to these types of matters, the outcome of such matters may be material to the Company's results of operations or cash flows in the period in which the impact of such matters is determined or paid.

*Reserves for General and Professional Liability Claims*

As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims. These suits could involve claims for substantial damages. Any professional liability litigation could also have an adverse impact on the Company's client base and reputation. The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures. The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims. Reserves for such matters, including those associated with both asserted and incurred but not reported claims, are established by considering actuarially determined losses based upon the Company's historical and projected loss experience. Such reserves totaled approximately \$137 million and \$130 million as of June 30, 2011 and December 31, 2010, respectively. Management believes that established reserves and present insurance coverage are sufficient to cover currently estimated exposures. Management cannot predict the outcome of any claims made against the Company. Although management does not anticipate that the ultimate outcome of any such proceedings or claims will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing accruals for loss estimates related to these types of matters, the outcome may be material to the Company's results of operations or cash flows in the period in which the impact of such claims is determined or paid.

**13. DISCONTINUED OPERATIONS**

Summarized financial information for the discontinued operations of NID, a test kit manufacturing subsidiary which was closed in 2006, is set forth below:

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2011	2010	2011	2010
Net revenues	\$ —	\$ —	\$ —	\$ —
Income (loss) from discontinued operations before income taxes	(190)	280	(282)	295
Income tax expense	(317)	(546)	(599)	(613)
Loss from discontinued operations, net of taxes	<u>\$ (507)</u>	<u>\$ (266)</u>	<u>\$ (881)</u>	<u>\$ (318)</u>

The remaining balance sheet information related to NID was not material at June 30, 2011 and December 31, 2010.

**14. BUSINESS SEGMENT INFORMATION**

Clinical testing is an essential element in the delivery of healthcare services. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. Clinical laboratory testing is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples. Anatomic pathology services are principally for the detection of cancer and are performed on tissues, such as biopsies, and other samples, such as human cells. Customers of the clinical testing business include patients, physicians, hospitals, employers, governmental institutions and other commercial clinical laboratories. The clinical testing business accounted for greater than 90% of net revenues from continuing operations in 2011 and 2010.

All other operating segments include the Company's non-clinical testing businesses and consist of its risk assessment services, clinical trials testing, healthcare information technology and diagnostics products businesses. The Company's risk assessment business provides underwriting support services to the life insurance industry including teleunderwriting, specimen collection and paramedical examinations, laboratory testing, medical record retrieval, case management, motor vehicle reports, telephone inspections, prescription histories and credit checks. The Company's clinical trials testing business provides clinical testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. The Company's healthcare information technology business is a developer and integrator of clinical connectivity and data management solutions for healthcare organizations, physicians and clinicians than can help improve patient care and medical practice. The Company's diagnostics products business manufactures and markets products that enable healthcare professionals to make healthcare diagnoses, including products for point-of-care testing for the professional market. During the second quarter of 2011, the Company acquired Athena and Celera (see Note 4 for further details). Athena is included in the Company's clinical laboratory testing business. The majority of Celera's operations are included in the Company's clinical laboratory testing business, with the remainder in other operating segments.

On April 19, 2006, the Company decided to discontinue NID's operations and results of operations for NID have been classified as discontinued operations for all periods presented (see Note 13).

At June 30, 2011, substantially all of the Company's services are provided within the United States, and substantially all of the Company's assets are located within the United States.

The following table is a summary of segment information for the three and six months ended June 30, 2011 and 2010. Segment asset information is not presented since it is not used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income for the segment. General management and administrative corporate expenses, including amortization of intangible assets and the charge to earnings in the first quarter of 2011 of \$236 million related to the settlement of the California Lawsuit (see Note 12), are included in general corporate expenses below. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the Consolidated Financial Statements contained in the Company's 2010 Annual Report on Form 10-K and Note 2 to the interim consolidated financial statements.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2011	2010	2011	2010
<b>Net revenues:</b>				
Clinical laboratory testing business	\$ 1,726,948	\$ 1,715,112	\$ 3,389,113	\$ 3,372,179
All other operating segments	176,253	159,615	335,665	308,051
Total net revenues	<u>\$ 1,903,201</u>	<u>\$ 1,874,727</u>	<u>\$ 3,724,778</u>	<u>\$ 3,680,230</u>
<b>Operating earnings (loss):</b>				
Clinical laboratory testing business	\$ 373,748	\$ 390,216	\$ 684,032	\$ 731,101
All other operating segments	14,766	16,944	22,625	18,506
General corporate expenses	(71,660)	(41,266)	(358,843)	(85,151)
Total operating income	<u>316,854</u>	<u>365,894</u>	<u>347,814</u>	<u>664,456</u>
Non-operating expenses, net	(39,058)	(36,101)	(67,080)	(58,080)
<b>Income from continuing operations before taxes</b>	<u>277,796</u>	<u>329,793</u>	<u>280,734</u>	<u>606,376</u>
<b>Income tax expense</b>	<u>105,762</u>	<u>125,651</u>	<u>154,988</u>	<u>231,029</u>
<b>Income from continuing operations</b>	<u>172,034</u>	<u>204,142</u>	<u>125,746</u>	<u>375,347</u>
<b>Loss from discontinued operations, net of taxes</b>	<u>(507)</u>	<u>(266)</u>	<u>(881)</u>	<u>(318)</u>
<b>Net income</b>	<u>171,527</u>	<u>203,876</u>	<u>124,865</u>	<u>375,029</u>
<b>Less: Net income attributable to noncontrolling interests</b>	<u>8,384</u>	<u>9,261</u>	<u>15,583</u>	<u>17,966</u>
<b>Net income attributable to Quest Diagnostics</b>	<u>\$ 163,143</u>	<u>\$ 194,615</u>	<u>\$ 109,282</u>	<u>\$ 357,063</u>

**15. SUBSEQUENT EVENT**

On July 14, 2011, the Company adopted a restructuring plan that it expects to complete within the third quarter of 2011. The Company anticipates incurring a charge of approximately \$20 million before tax (approximately \$12 million after tax) in the third quarter of 2011, principally associated with workforce reduction costs, consisting primarily of severance and related benefits. The Company expects that the full amount of the charge will result in future cash expenditures.

**16. SUMMARIZED FINANCIAL INFORMATION**

The Company's Senior Notes due 2011, Floating Rate Senior Notes due 2014, Senior Notes due 2015, Senior Notes due 2016, Senior Notes due 2017, Senior Notes due 2020, Senior Notes due 2021, Senior Notes due 2037 and Senior Notes due 2040 are fully and unconditionally guaranteed, jointly and severally, by the Subsidiary Guarantors. With the exception of Quest Diagnostics Receivables Incorporated ("QDRI") (see paragraph below), the non-guarantor subsidiaries are primarily foreign subsidiaries and less than wholly-owned subsidiaries.

In conjunction with the Company's secured receivables credit facility, the Company maintains a wholly-owned non-guarantor subsidiary, QDRI. The Company and certain of its Subsidiary Guarantors transfer certain domestic receivables to QDRI. QDRI utilizes the transferred receivables to collateralize borrowings under the Company's secured receivables credit facility. The Company and the Subsidiary Guarantors provide collection services to QDRI. QDRI uses cash collections principally to purchase new receivables from the Company and the Subsidiary Guarantors.

The following condensed consolidating financial data illustrates the composition of the combined guarantors. Investments in subsidiaries are accounted for by the parent using the equity method for purposes of the supplemental

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
**(dollars in thousands unless otherwise indicated)**

consolidating presentation. Earnings (losses) of subsidiaries are therefore reflected in the parent's investment accounts and earnings. The principal elimination entries relate to investments in subsidiaries and intercompany balances and transactions.

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

*Condensed Consolidating Statement of Operations*  
*Three Months Ended June 30, 2011*

	Parent	Subsidiary Guarantors	Non- Guarantor Subsidiaries	Eliminations	Consolidated
Net revenues	\$ 203,321	\$ 1,577,305	\$ 189,592	\$ (67,017)	\$ 1,903,201
Operating costs and expenses:					
Cost of services	121,342	909,681	73,371	—	1,104,394
Selling, general and administrative	35,526	342,577	92,150	(7,464)	462,789
Amortization of intangible assets	543	16,048	2,001	—	18,592
Royalty (income) expense	(104,418)	104,418	—	—	—
Other operating expense (income), net	28	585	(41)	—	572
Total operating costs and expenses	53,021	1,373,309	167,481	(7,464)	1,586,347
Operating income	150,300	203,996	22,111	(59,553)	316,854
Non-operating (expense) income, net	(45,706)	(53,301)	396	59,553	(39,058)
Income from continuing operations before taxes	104,594	150,695	22,507	—	277,796
Income tax expense	40,382	59,578	5,802	—	105,762
Income from continuing operations	64,212	91,117	16,705	—	172,034
Loss from discontinued operations, net of taxes	—	(507)	—	—	(507)
Equity earnings from subsidiaries	98,931	—	—	(98,931)	—
Net income	163,143	90,610	16,705	(98,931)	171,527
Less: Net income attributable to noncontrolling interests	—	—	8,384	—	8,384
Net income attributable to Quest Diagnostics	\$ 163,143	\$ 90,610	\$ 8,321	\$ (98,931)	\$ 163,143

*Condensed Consolidating Statement of Operations*  
*Three Months Ended June 30, 2010*

	Parent	Subsidiary Guarantors	Non- Guarantor Subsidiaries	Eliminations	Consolidated
Net revenues	\$ 218,419	\$ 1,540,722	\$ 181,373	\$ (65,787)	\$ 1,874,727
Operating costs and expenses:					
Cost of services	129,236	886,783	62,952	—	1,078,971
Selling, general and administrative	21,273	312,465	93,236	(7,562)	419,412
Amortization of intangible assets	18	7,601	1,651	—	9,270
Royalty (income) expense	(105,316)	105,316	—	—	—
Other operating (income) expense, net	(1,346)	233	2,293	—	1,180
Total operating costs and expenses	43,865	1,312,398	160,132	(7,562)	1,508,833
Operating income	174,554	228,324	21,241	(58,225)	365,894
Non-operating (expense) income, net	(39,974)	(54,940)	588	58,225	(36,101)
Income from continuing operations before taxes	134,580	173,384	21,829	—	329,793
Income tax expense	52,577	67,331	5,743	—	125,651
Income from continuing operations	82,003	106,053	16,086	—	204,142
Loss from discontinued operations, net of taxes	—	(266)	—	—	(266)
Equity earnings from subsidiaries	112,612	—	—	(112,612)	—
Net income	194,615	105,787	16,086	(112,612)	203,876
Less: Net income attributable to noncontrolling interests	—	—	9,261	—	9,261
Net income attributable to Quest Diagnostics	\$ 194,615	\$ 105,787	\$ 6,825	\$ (112,612)	\$ 194,615

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

*Condensed Consolidating Statement of Operations*  
*Six Months Ended June 30, 2011*

	Parent	Subsidiary Guarantors	Non- Guarantor Subsidiaries	Eliminations	Consolidated
Net revenues	\$ 401,810	\$ 3,080,649	\$ 380,879	\$ (138,560)	\$ 3,724,778
Operating costs and expenses:					
Cost of services	244,933	1,817,071	139,388	—	2,201,392
Selling, general and administrative	73,962	654,306	197,203	(14,824)	910,647
Amortization of intangible assets	706	24,197	3,538	—	28,441
Royalty (income) expense	(206,774)	206,774	—	—	—
Other operating expense (income), net	236,306	371	(193)	—	236,484
Total operating costs and expenses	349,133	2,702,719	339,936	(14,824)	3,376,964
Operating income	52,677	377,930	40,943	(123,736)	347,814
Non-operating (expense) income, net	(84,126)	(110,455)	3,765	123,736	(67,080)
Income (loss) from continuing operations before taxes	(31,449)	267,475	44,708	—	280,734
Income tax expense	36,768	105,743	12,477	—	154,988
Income (loss) from continuing operations	(68,217)	161,732	32,231	—	125,746
Loss from discontinued operations, net of taxes	—	(881)	—	—	(881)
Equity earnings from subsidiaries	177,499	—	—	(177,499)	—
Net income	109,282	160,851	32,231	(177,499)	124,865
Less: Net income attributable to noncontrolling interests	—	—	15,583	—	15,583
Net income attributable to Quest Diagnostics	\$ 109,282	\$ 160,851	\$ 16,648	\$ (177,499)	\$ 109,282

*Condensed Consolidating Statement of Operations*  
*Six Months Ended June 30, 2010*

	Parent	Subsidiary Guarantors	Non- Guarantor Subsidiaries	Eliminations	Consolidated
Net revenues	\$ 429,640	\$ 3,023,312	\$ 373,709	\$ (146,431)	\$ 3,680,230
Operating costs and expenses:					
Cost of services	251,823	1,766,570	126,951	—	2,145,344
Selling, general and administrative	44,351	626,583	194,104	(14,893)	850,145
Amortization of intangible assets	35	15,232	3,362	—	18,629
Royalty (income) expense	(206,808)	206,808	—	—	—
Other operating (income) expense, net	(321)	466	1,511	—	1,656
Total operating costs and expenses	89,080	2,615,659	325,928	(14,893)	3,015,774
Operating income	340,560	407,653	47,781	(131,538)	664,456
Non-operating (expense) income, net	(70,533)	(121,385)	2,300	131,538	(58,080)
Income from continuing operations before taxes	270,027	286,268	50,081	—	606,376
Income tax expense	104,062	113,078	13,889	—	231,029
Income from continuing operations	165,965	173,190	36,192	—	375,347
Loss from discontinued operations, net of taxes	—	(318)	—	—	(318)
Equity earnings from subsidiaries	191,098	—	—	(191,098)	—
Net income	357,063	172,872	36,192	(191,098)	375,029
Less: Net income attributable to noncontrolling interests	—	—	17,966	—	17,966
Net income attributable to Quest Diagnostics	\$ 357,063	\$ 172,872	\$ 18,226	\$ (191,098)	\$ 357,063

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

Condensed Consolidating Balance Sheet  
June 30, 2011

	Parent	Subsidiary Guarantors	Non- Guarantor Subsidiaries	Eliminations	Consolidated
<b>Assets</b>					
Current assets:					
Cash and cash equivalents	\$ 138,157	\$ 2,484	\$ 43,577	\$ —	\$ 184,218
Accounts receivable, net	22,222	163,482	743,668	—	929,372
Other current assets	75,339	186,666	102,360	—	364,365
Total current assets	235,718	352,632	889,605	—	1,477,955
Property, plant and equipment, net	169,607	609,465	41,521	—	820,593
Goodwill and intangible assets, net	155,529	6,260,302	483,309	—	6,899,140
Intercompany (payable) receivable	(461,060)	739,576	(278,516)	—	—
Investment in subsidiaries	7,788,982	—	—	(7,788,982)	—
Other assets	274,555	43,974	50,321	(135,347)	233,503
Total assets	\$ 8,163,331	\$ 8,005,949	\$ 1,186,240	\$ (7,924,329)	\$ 9,431,191
<b>Liabilities and Stockholders' Equity</b>					
Current liabilities:					
Accounts payable and accrued expenses	\$ 786,734	\$ 161,246	\$ 50,702	\$ —	\$ 998,682
Short-term borrowings and current portion of long-term debt	763,683	144,699	86,293	—	994,675
Total current liabilities	1,550,417	305,945	136,995	—	1,993,357
Long-term debt	2,989,123	18,378	325,430	—	3,332,931
Other liabilities	194,641	541,596	53,417	(135,347)	654,307
Stockholders' equity:					
Quest Diagnostics stockholders' equity	3,429,150	7,140,030	648,952	(7,788,982)	3,429,150
Noncontrolling interests	—	—	21,446	—	21,446
Total stockholders' equity	3,429,150	7,140,030	670,398	(7,788,982)	3,450,596
Total liabilities and stockholders' equity	\$ 8,163,331	\$ 8,005,949	\$ 1,186,240	\$ (7,924,329)	\$ 9,431,191

**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

Condensed Consolidating Balance Sheet  
December 31, 2010

	Parent	Subsidiary Guarantors	Non- Guarantor Subsidiaries	Eliminations	Consolidated
<b>Assets</b>					
Current assets:					
Cash and cash equivalents	\$ 392,525	\$ 928	\$ 55,848	\$ —	\$ 449,301
Accounts receivable, net	15,913	135,417	693,969	—	845,299
Other current assets	55,723	165,099	96,183	(6,188)	310,817
Total current assets	464,161	301,444	846,000	(6,188)	1,605,417
Property, plant and equipment, net	179,624	616,114	38,638	—	834,376
Goodwill and intangible assets, net	155,596	5,279,371	463,376	—	5,898,343
Intercompany receivable (payable)	84,107	231,268	(315,375)	—	—
Investment in subsidiaries	6,195,557	—	—	(6,195,557)	—
Other assets	227,822	10,090	48,319	(96,737)	189,494
Total assets	\$ 7,306,867	\$ 6,438,287	\$ 1,080,958	\$ (6,298,482)	\$ 8,527,630
<b>Liabilities and Stockholders' Equity</b>					
Current liabilities:					
Accounts payable and accrued expenses	\$ 623,610	\$ 190,334	\$ 57,516	\$ (6,188)	\$ 865,272
Current portion of long-term debt	203,659	144,004	1,333	—	348,996
Total current liabilities	827,269	334,338	58,849	(6,188)	1,214,268
Long-term debt	2,295,709	19,342	326,109	—	2,641,160
Other liabilities	150,409	512,681	51,724	(96,737)	618,077
Stockholders' equity:					
Quest Diagnostics stockholders' equity	4,033,480	5,571,926	623,631	(6,195,557)	4,033,480
Noncontrolling interests	—	—	20,645	—	20,645
Total stockholders' equity	4,033,480	5,571,926	644,276	(6,195,557)	4,054,125
Total liabilities and stockholders' equity	\$ 7,306,867	\$ 6,438,287	\$ 1,080,958	\$ (6,298,482)	\$ 8,527,630



**QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED**  
(dollars in thousands unless otherwise indicated)

*Condensed Consolidating Statement of Cash Flows*  
*Six Months Ended June 30, 2011*

	Parent	Subsidiary Guarantors	Non- Guarantor Subsidiaries	Eliminations	Consolidated
<b>Cash flows from operating activities:</b>					
Net income	\$ 109,282	\$ 160,851	\$ 32,231	\$ (177,499)	\$ 124,865
Adjustments to reconcile net income to net cash provided by (used in) operating activities:					
Depreciation and amortization	22,889	104,703	8,492	—	136,084
Provision for doubtful accounts	2,376	27,950	115,659	—	145,985
Provision for special charge	236,000	—	—	—	236,000
Other, net	(195,421)	67,472	(3,824)	177,499	45,726
Changes in operating assets and liabilities	(151,255)	(161,149)	(156,173)	—	(468,577)
Net cash provided by (used in) operating activities	23,871	199,827	(3,615)	—	220,083
Net cash used in investing activities	(1,059,870)	(169,185)	(5,315)	226,404	(1,007,966)
Net cash provided by (used in) financing activities	781,631	(29,086)	(3,341)	(226,404)	522,800
Net change in cash and cash equivalents	(254,368)	1,556	(12,271)	—	(265,083)
Cash and cash equivalents, beginning of period	392,525	928	55,848	—	449,301
Cash and cash equivalents, end of period	\$ 138,157	\$ 2,484	\$ 43,577	\$ —	\$ 184,218

*Condensed Consolidating Statement of Cash Flows*  
*Six Months Ended June 30, 2010*

	Parent	Subsidiary Guarantors	Non- Guarantor Subsidiaries	Eliminations	Consolidated
<b>Cash flows from operating activities:</b>					
Net income	\$ 357,063	\$ 172,872	\$ 36,192	\$ (191,098)	\$ 375,029
Adjustments to reconcile net income to net cash provided by operating activities:					
Depreciation and amortization	24,331	93,907	8,069	—	126,307
Provision for doubtful accounts	3,006	24,669	120,728	—	148,403
Other, net	(131,368)	(6,194)	(17,401)	191,098	36,135
Changes in operating assets and liabilities	82,079	(196,396)	(123,173)	—	(237,490)
Net cash provided by operating activities	335,111	88,858	24,415	—	448,384
Net cash provided by (used in) investing activities	11,063	(68,458)	(2,763)	(31,886)	(92,044)
Net cash used in financing activities	(424,511)	(26,208)	(23,875)	31,886	(442,708)
Net change in cash and cash equivalents	(78,337)	(5,808)	(2,223)	—	(86,368)
Cash and cash equivalents, beginning of period	464,958	17,457	51,841	—	534,256
Cash and cash equivalents, end of period	\$ 386,621	\$ 11,649	\$ 49,618	\$ —	\$ 447,888

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

### **Critical Accounting Policies**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions and select accounting policies that affect our reported financial results and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

While many operational aspects of our business are subject to complex federal, state and local regulations, the accounting for most of our business is generally straightforward with net revenues primarily recognized upon completion of the testing process. Our revenues are primarily comprised of a high volume of relatively low dollar transactions, and about one-half of our total costs and expenses consist of employee compensation and benefits. Due to the nature of our business, several of our accounting policies involve significant estimates and judgments. These accounting policies have been described in our Annual Report on Form 10-K for the year ended December 31, 2010.

### **Initiatives to Improve Operating Efficiency**

The diagnostic testing industry is labor intensive. Employee compensation and benefits constitute approximately one-half of our total costs and expenses. Cost of services consists principally of costs for obtaining, transporting and testing specimens. Selling, general and administrative expenses consist principally of the costs associated with our sales and marketing efforts, billing operations, bad debt expense and general management and administrative support. In addition, performing diagnostic testing involves significant fixed costs for facilities and other infrastructure required to obtain, transport and test specimens. Therefore, relatively small changes in volume can have a significant impact on profitability in the short-term.

A large portion of our costs are fixed, making it more challenging to fully mitigate the profit impact of reduced volume in the short term. In response to reduced volume levels, as a result of a temporary slowdown in healthcare utilization, we have implemented a number of actions in July 2011 to align our costs with reduced volume levels. These cost actions, which are broad in nature and affect most parts of our business, will result in a charge to earnings in the third quarter of 2011 estimated at approximately \$20 million, comprised principally of employee separation costs.

In addition, in July 2011 we announced a multi-year program designed to reduce our cost structure by \$500 million over the next three years. This effort is intended to address continued reimbursement pressures and labor and benefit cost increases, free up additional resources to invest in science and innovation, and enable us to improve operating profitability. As detailed plans to implement these opportunities are approved and executed, it likely will result in charges to earnings associated with the implementation. These charges may be material to the results of operations and cash flows in the periods recorded or paid.

### **Acquisitions**

#### *Acquisition of Athena Diagnostics*

On February 24, 2011, we signed a definitive agreement to acquire Athena Diagnostics ("Athena") from Thermo Fisher Scientific, Inc., in an all-cash transaction valued at approximately \$740 million. Athena is the leading provider of advanced diagnostic tests related to neurological conditions, and generated revenues of approximately \$110 million in 2010. We completed the acquisition of Athena on April 4, 2011 (see Note 4 to the interim consolidated financial statements for further details).

### *Acquisition of Celera Corporation*

On March 17, 2011, we entered into a definitive merger agreement with Celera Corporation ("Celera") under which we agreed to acquire Celera for \$8 per share, in a transaction valued at approximately \$341 million, net of \$326 million in acquired cash and short-term marketable securities. Additionally, we expect to utilize Celera's available tax credits, net operating loss carryforwards and capitalized tax research and development expenditures to reduce our future tax payments by approximately \$110 million. Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Celera generated revenues of \$128 million in 2010. We completed the acquisition of Celera on May 17, 2011.

Of the total purchase price of \$667 million to acquire Celera, \$508 million was paid through June 30, 2011. Accounts payable and accrued expenses at June 30, 2011 included a liability of \$159 million representing the remaining merger consideration related to shares of Celera which had not been surrendered as of June 30, 2011. We expect to fund the payment of the remaining merger consideration with cash on hand and existing credit facilities. See Note 4 to the interim consolidated financial statements for further details.

### **Results of Operations**

Our clinical testing business currently represents our one reportable business segment. In both 2011 and 2010, our clinical testing business accounted for greater than 90% of net revenues. Our other operating segments consist of our risk assessment services, clinical trials testing, healthcare information technology and diagnostic products businesses. Our business segment information is disclosed in Note 14 to the interim consolidated financial statements.

### ***Settlement Related to the California Lawsuit***

As a result of settlement discussions which resumed in the first quarter of 2011, on May 9, 2011, we announced an agreement in principle to resolve a previously disclosed civil lawsuit brought by a California competitor in which the State of California intervened (the "California Lawsuit"). In the lawsuit, the plaintiffs alleged, among other things, that we overcharged Medi-Cal for testing services and violated the California False Claims Act. Specifically, the plaintiffs alleged, among other things, that we violated certain regulations that govern billing to Medi-Cal ("Comparable Charge" regulations). While denying liability, in order to avoid the uncertainty, expense and risks of litigation, we agreed to resolve these matters for \$241 million. On May 19, 2011, we finalized a settlement agreement and release with the California Department of Health Care Services, the California Attorney General's Office and the *qui tam* relator. We agreed to the settlement to resolve claims pertaining to the Comparable Charge allegations; we received a full release of these and all other allegations in the complaint. We also agreed to certain reporting obligations regarding our pricing for a limited time period and, at our option in lieu of such obligations for a transitional period, to provide Medi-Cal with a discount (the "Transitional Discount") until the end of July 2012. The Transitional Discount, to the extent provided, is not expected to have a material impact on our consolidated revenues or results of operations.

As provided for in the settlement agreement, we have resumed billing for unbilled services and expect to be reimbursed for all services provided prior to the effective date of the final settlement agreement. Such reimbursement is expected to be consistent with the related amounts accrued.

As a result of the agreement in principle, we recorded a pre-tax charge to earnings in the first quarter of 2011 of \$236 million (the "Medi-Cal charge"), or \$1.20 per diluted share, which represented the cost to resolve the matters noted above and related claims, less amounts previously reserved for related matters.

We funded the \$241 million payment in the second quarter of 2011 with cash on hand and borrowings under our existing credit facilities. See Note 12 to the interim consolidated financial statements for further details.

*Three and Six Months Ended June 30, 2011 Compared with Three and Six Months Ended June 30, 2010*

*Continuing Operations*

	Three Months Ended June 30,		% Change Increase (decrease)	Six Months Ended June 30,		% Change Increase (decrease)
	2011	2010		2011	2010	
	(dollars in millions, except per share data)					
Net revenues	\$ 1,903.2	\$ 1,874.7	1.5%	\$ 3,724.8	\$ 3,680.2	1.2%
Income from continuing operations	163.6	194.9	(16.1)%	110.2	357.4	(69.2)%
Earnings per diluted share	\$ 1.02	\$ 1.07	(4.7)%	\$ 0.68	\$ 1.96	(65.3)%

Results for the three months ended June 30, 2011 included pre-tax charges of \$21.2 million, or \$0.10 per diluted share, associated with the acquisitions of Athena and Celera. Of these costs, \$20.4 million, primarily related to professional fees and integration charges, were recorded in selling, general and administrative expenses and \$0.8 million of financing related costs were included in interest expense, net.

Results for the six months ended June 30, 2011 were affected by a number of items which impacted earnings per diluted share by \$1.44. During the first quarter of 2011, we recorded the Medi-Cal charge of \$236 million, or \$1.20 per diluted share, in "other operating expense, net." In addition, results for the six months ended June 30, 2011 included pre-tax charges of \$25.8 million, or \$0.12 per diluted share, associated with the acquisitions of Athena and Celera. Of these costs \$22.7 million, primarily related to professional fees and integration charges, were recorded in selling, general and administrative expenses and \$3.1 million of financing related costs were included in interest expense, net. Results for the six months ended June 30, 2011 also included \$13.3 million of pre-tax charges, or \$0.05 per diluted share, principally associated with workforce reductions. Of these costs, \$9.0 million and \$4.3 million were included in cost of services and selling, general and administrative expenses, respectively. In addition, we estimate that the impact of severe weather during the first quarter of 2011 adversely affected operating income for the six months ended June 30, 2011 by \$18.5 million, or \$0.07 per diluted share.

Results for the six months ended June 30, 2010 were affected by a number of items which impacted earnings per diluted share by \$0.11. During the first quarter of 2010, we recorded pre-tax charges of \$17.3 million, or \$0.06 per diluted share, principally associated with workforce reductions. Of these costs, \$4.5 million and \$12.8 million were included in cost of services and selling, general and administrative expenses, respectively. In addition, we estimate that the impact of severe weather during the first quarter of 2010 adversely affected operating income for the six months ended June 30, 2010 by \$14.1 million, or \$0.05 per diluted share.

*Net Revenues*

Net revenues for the three months ended June 30, 2011 were 1.5% above the prior year level with the Athena and Celera acquisitions contributing 2.5% revenue growth in the quarter.

Clinical testing revenue, which accounted for over 90% of our consolidated revenues, increased by 0.7% for the three months ended June 30, 2011 over the prior year period. The acquisitions of Athena and Celera contributed about 2.2% to the clinical testing revenue growth in the quarter. Clinical testing volume, measured by the number of requisitions, decreased by 0.9% for the second quarter of 2011 compared to the prior year period due to continued market softness, as measured by physician office visits in the second quarter of 2011. The clinical testing volume contributed by the Athena and Celera acquisitions had a modest positive impact in the quarter. Pre-employment drug testing volume, which has continued to rebound, grew about 6% in the quarter.

Revenue per requisition for the three months ended June 30, 2011 was 1.6% above the prior year period, with the improvement driven by an increase in esoteric testing mix from the acquired operations of Athena and Celera. While revenue per requisition is benefiting from an increased mix in gene-based and esoteric testing, it continues to be pressured by business and payer mix changes, the 1.75% Medicare fee schedule decrease, which went into effect January 1, 2011,

and pricing changes in connection with several large contract extensions executed in the first half of last year. The business and payer mix changes, which continue to pressure revenue per requisition, include the further rebound in our lower-priced drugs-of-abuse testing, and continued weakness in our higher priced anatomic pathology testing services.

Net revenues for the six months ended June 30, 2011 were 1.2% above the prior year level with the Athena and Celera acquisitions contributing 1.3% to consolidated revenue growth.

Clinical testing revenue, which accounted for over 90% of our consolidated revenues, grew 0.5%. The acquisitions of Athena and Celera contributed about 1.1% to the clinical testing revenue growth for the six months ended June 30, 2011. Clinical testing volume, measured by the number of requisitions, increased by 0.5% compared to the prior year period. Pre-employment drug testing volume, which has continued to rebound, grew about 8% during the six months ended June 30, 2011.

Revenue per requisition for the six months ended June 30, 2011 approximated the prior year level. Revenue per requisition continues to benefit from an increased mix in gene-based and esoteric testing, particularly from the impact of the acquired operations of Athena and Celera. Offsetting this benefit was business and payor mix changes including: an increase in lower priced drugs-of-abuse testing and a decrease in higher priced anatomic pathology testing; price changes in connection with several large contract extensions executed in the first half of last year; and the 1.75% Medicare fee schedule decrease, which went into effect January 1, 2011.

Our businesses other than clinical laboratory testing accounted for approximately 9% of our net revenues for the three and six months ended June 30, 2011 and 2010. These businesses include our risk assessment services, clinical trials testing, healthcare information technology, and diagnostic products businesses. For the three and six months ended June 30, 2011, revenue in our non-clinical testing businesses, which contain most of our international operations, grew by approximately 10% and 9%, respectively, and benefited from the impact of the Celera acquisition and foreign currency exchange rates.

*Operating Costs and Expenses*

	<b>Three Months Ended June 30,</b>					
	<b>2011</b>		<b>2010</b>		<b>Change Increase (decrease)</b>	
	<b>\$</b>	<b>% Net Revenue</b>	<b>\$</b>	<b>% Net Revenue</b>	<b>\$</b>	<b>% Net Revenue</b>
	(dollars in millions)					
Cost of services	\$ 1,104.4	58.0%	\$ 1,078.9	57.6%	\$ 25.5	0.4%
Selling, general and administrative expenses (SG&A)	462.8	24.3%	419.4	22.4%	43.4	1.9%
Amortization of intangible assets	18.6	1.0%	9.3	0.5%	9.3	0.5%
Other operating expense, net	0.6	0.1%	1.2	—%	(0.6)	0.1%
<b>Total operating costs and expenses</b>	<b>\$ 1,586.4</b>	<b>83.4%</b>	<b>\$ 1,508.8</b>	<b>80.5%</b>	<b>\$ 77.6</b>	<b>2.9%</b>
Bad debt expense (included in SG&A)	\$ 68.6	3.6%	\$ 72.1	3.8%	\$ (3.5)	(0.2)%

**Six Months Ended June 30,**

	2011		2010		Change Increase (decrease)	
	\$	% Net Revenue	\$	% Net Revenue	\$	% Net Revenue
	(dollars in millions)					
Cost of services	\$ 2,201.4	59.1%	\$ 2,145.3	58.3%	\$ 56.1	0.8%
Selling, general and administrative expenses (SG&A)	910.6	24.4%	850.1	23.1%	60.5	1.3%
Amortization of intangible assets	28.5	0.8%	18.6	0.5%	9.9	0.3%
Other operating expense, net	236.5	6.4%	1.7	—%	234.8	6.4%
<b>Total operating costs and expenses</b>	<b>\$ 3,377.0</b>	<b>90.7%</b>	<b>\$ 3,015.7</b>	<b>81.9%</b>	<b>\$ 361.3</b>	<b>8.8%</b>
Bad debt expense (included in SG&A)	\$ 146.0	3.9%	\$ 148.4	4.0%	\$ (2.4)	(0.1)%
<i>Total Operating Costs and Expenses</i>						

For the second quarter of 2011, the impacts of the higher costs associated with employee compensation and benefits, investments we have made in our sales force and service capabilities, the addition of the Athena and Celera operations, as well as costs related to the Athena and Celera transactions, served to increase total operating expenses as a percent of net revenues compared to the prior year period. Partially offsetting these increases was a year-over-year reduction in costs associated with actions we have taken to adjust our cost structure, primarily associated with workforce reductions. Results for the second quarter of 2011 included pre-tax charges of \$20.4 million, primarily related to professional fees and integration charges associated with the acquisitions of Athena and Celera, which served to increase operating expenses as a percent of net revenues by 1.1%.

For the six months ended June 30, 2011, the impacts of the Medi-Cal charge, severe weather, higher costs associated with employee compensation and benefits, and investments we have made in our sales force and service capabilities, as well as the impact of the Athena and Celera acquisitions, served to increase total operating expenses as a percent of net revenues compared to the prior year period. Partially offsetting these increases was a year-over-year reduction in costs associated with actions we have taken to adjust our cost structure, primarily associated with workforce reductions. Results for the six months ended June 30, 2011 included the Medi-Cal charge of \$236 million recorded in connection with the California Lawsuit. In addition, results for the six months ended June 30, 2011 and 2010 included pre-tax charges, principally associated with workforce reductions, of \$13.3 million (\$9.0 million in cost of services and \$4.3 million in selling, general and administrative expenses) and \$17.3 million (\$4.5 million in cost of services and \$12.8 million in selling, general and administrative expenses), respectively. Selling, general and administrative expenses for the six months ended June 30, 2011 also included \$22.7 million of pre-tax charges, primarily related to professional fees and integration charges associated with the acquisitions of Athena and Celera.

Also, year-over-year comparisons for both the three and six months ended June 30, 2011 were unfavorably impacted by approximately \$4 million associated with gains on investments in our supplemental deferred compensation plans. Under our supplemental deferred compensation plans, employee compensation deferrals, together with Company matching contributions, are invested in a variety of investments held in trusts. Gains and losses associated with the investments are recorded in earnings within "other (expense) income, net." A corresponding and offsetting adjustment is also recorded to the deferred compensation obligation to reflect investment gains and losses earned by the employee. Such adjustments to the deferred compensation obligation are recorded in earnings principally within "selling, general and administrative expenses" and offset the amount of investment gains and losses recorded in "other (expense) income, net." Results for the three and six months ended June 30, 2011 included an increase in operating costs of \$0.2 million and \$2.3 million, respectively, representing increases in the deferred compensation obligation to reflect investment gains earned by employees participating in our deferred compensation plans. Results for the three and six months ended June 30, 2010 included a reduction in operating costs of \$3.9 million and \$1.4 million, respectively, representing decreases in

the deferred compensation obligation to reflect investment losses incurred by employees participating in our deferred compensation plans.

#### *Cost of Services*

The increase in cost of services as a percentage of net revenues for the three months ended June 30, 2011 compared to the prior year period primarily reflects higher costs associated with employee compensation and benefits, and investments we have made in service capabilities, partially offset by an increase in revenue per requisition, attributable to the acquired operations of Athena and Celera.

The increase in cost of services as a percentage of revenues for the six months ended June 30, 2011 compared to the prior year period reflects the impact of severe weather in the first quarter, a \$4.5 million increase in pre-tax charges associated with workforce reductions and higher costs associated with employee compensation and benefits, and investments we have made in service capabilities. These increases have been partially offset by the acquired operations of Athena and Celera, which served to reduce the percentage.

#### *Selling, General and Administrative Expenses*

The increase in selling, general and administrative expenses as a percentage of net revenues for the three months ended June 30, 2011 compared to the prior year period primarily reflects pre-tax charges of \$20.4 million, primarily related to professional fees and integration charges, associated with the acquisitions of Athena and Celera, higher costs associated with employee compensation and benefits, investments we have made in our sales force and the impact of the Celera operations.

The increase in selling, general and administrative expenses as a percentage of net revenues for the six months ended June 30, 2011 compared to the prior year period primarily reflects the impact of severe weather, higher costs associated with employee compensation and benefits and investments we have made in our sales force. In addition, selling, general and administrative expenses for the six months ended June 30, 2011 included pre-tax charges of \$22.7 million, primarily related to professional fees and integration charges associated with the acquisitions of Athena and Celera. These increases were partially offset by an \$8.5 million decrease in pre-tax charges associated with workforce reductions.

For the three months and six months ended June 30, 2011, bad debt expense as a percentage of net revenues improved compared to the prior year periods, primarily reflecting continued strong performance in our billing operations and collection metrics.

#### *Amortization of Intangible Assets*

The increase in amortization of intangible assets for the three and six months ended June 30, 2011 compared to the prior year periods reflects the impact of amortization of intangible assets acquired as part of the Athena and Celera acquisitions.

#### *Other Operating Expense, net*

Other operating expense, net includes special charges, and miscellaneous income and expense items related to operating activities. For the six months ended June 30, 2011, other operating expense, net included the Medi-Cal charge of \$236 million recorded in connection with the California Lawsuit.

*Operating Income*

	Three Months Ended June 30,		Change Increase (decrease)	Six Months Ended June 30,		Change Increase (decrease)
	2011	2010		2011	2010	
	(dollars in millions)					
Operating income	\$ 316.9	\$ 365.9	\$ (49.0)	\$ 347.8	\$ 664.5	\$ (316.7)
Operating income % of net revenues	16.6%	19.5%	(2.9)%	9.3%	18.1%	(8.8)%

For the second quarter of 2011, the impacts of the higher costs associated with employee compensation and benefits, investments we have made in our sales force and service capabilities, and the addition of the operations of Athena and Celera, as well as costs related to the Athena and Celera transactions, served to decrease operating income as a percent of net revenues compared to the prior year period. Partially offsetting these decreases was a year-over-year reduction in costs associated with actions we have taken to adjust our cost structure.

For the six months ended June 30, 2011, the impacts of the Medi-Cal charge, severe weather, higher costs associated with employee compensation and benefits, and investments we have made in our sales force and service capabilities, as well as costs related to the Athena and Celera transactions, served to decrease operating income as a percent of net revenues compared to the prior year period. Partially offsetting these decreases was a year-over-year reduction in costs associated with actions we have taken to adjust our cost structure.

*Interest Expense, net*

	Three Months Ended June 30,		Change Increase (decrease)	Six Months Ended June 30,		Change Increase (decrease)
	2011	2010		2011	2010	
	(dollars in millions)					
Interest expense, net	\$ 46.6	\$ 36.4	\$ 10.2	\$ 84.5	\$ 72.3	\$ 12.2

Interest expense, net for the three and six months ended June 30, 2011 increased from the prior year period primarily due to incremental debt of approximately \$1.3 billion, used to partially fund \$835 million of share repurchases and approximately \$1 billion paid for acquisitions. In addition, for the three and six months ended June 30, 2011, interest expense, net included \$0.8 million and \$3.1 million, respectively, of financing commitment fees related to the acquisition of Celera which were expensed. See Note 8 to the interim financial statements for further details regarding our senior notes offering.



*Other (Expense) Income, net*

Other (expense) income, net represents miscellaneous income and expense items related to non-operating activities, such as gains and losses associated with investments and other non-operating assets. For the three and six months ended June 30, 2011 and 2010, other (expense) income, net consisted of the following:

	Three Months Ended June 30,		Change Increase (decrease)	Six Months Ended June 30,		Change Increase (decrease)
	2011	2010		2011	2010	
	(dollars in millions)					
Investment gains (losses) associated with our supplemental deferred compensation plans	\$ 0.2	\$ (3.9)	\$ 4.1	\$ 2.3	\$ (1.4)	\$ 3.7
(Loss) gain on an investment	—	(3.3)	3.3	(0.2)	0.7	(0.9)
Other (expense) income items, net	(0.5)	0.1	(0.6)	(0.2)	(0.4)	0.2
Total other (expense) income, net	\$ (0.3)	\$ (7.1)	\$ 6.8	\$ 1.9	\$ (1.1)	\$ 3.0

*Income Tax Expense*

	Three Months Ended June 30,		Change Increase (decrease)	Six Months Ended June 30,		Change Increase (decrease)
	2011	2010		2011	2010	
Effective income tax rate	38.1%	38.1%	—	55.2%	38.1%	17.1%

The increase in the effective income tax rate for the six months ended June 30, 2011 is primarily due to the Medi-Cal charge recorded in the first quarter of 2011 associated with the California Lawsuit (see Note 12 to the interim consolidated financial statements), a portion for which a tax benefit has not been recorded.

*Discontinued Operations*

Loss from discontinued operations, net of taxes, for the three months ended June 30, 2011 and 2010 was \$0.5 million and \$0.3 million, respectively, with no impact on diluted earnings per share. Loss from discontinued operations for the six months ended June 30, 2011 was \$0.9 million, or \$0.01 per diluted share. For the six months ended June 30, 2010, loss from discontinued operations was \$0.3 million with no impact on diluted earnings per share. See Note 13 to the interim consolidated financial statements for further details.

**Quantitative and Qualitative Disclosures About Market Risk**

We address our exposure to market risks, principally the market risk of changes in interest rates, through a controlled program of risk management that includes the use of derivative financial instruments. We do not hold or issue derivative financial instruments for trading purposes. We believe that our exposures to foreign exchange impacts and changes in commodity prices are not material to our consolidated financial condition or results of operations. See Note 9 to the interim consolidated financial statements for additional discussion of our financial instruments and hedging activities.

At June 30, 2011 and December 31, 2010, the fair value of our debt was estimated at approximately \$4.6 billion and \$3.1 billion, respectively, using quoted market prices and yields for the same or similar types of borrowings, taking into account the underlying terms of the debt instruments. At June 30, 2011 and December 31, 2010, the estimated fair value exceeded the carrying value of the debt by \$228 million and \$80 million, respectively. A hypothetical 10% increase in interest rates (representing 41 basis points and 45 basis points at June 30, 2011 and December 31, 2010, respectively) would potentially reduce the estimated fair value of our debt by approximately \$119 million and \$89 million at June 30, 2011 and December 31, 2010, respectively.

Borrowings under our floating rate senior notes due 2014, our term loan due May 2012, our senior unsecured revolving credit facility and our secured receivables credit facility are subject to variable interest rates. Interest on our secured receivables credit facility is based on rates that are intended to approximate commercial paper rates for highly-rated issuers. Interest on our term loan due May 2012 and our senior unsecured revolving credit facility are subject to a pricing schedule that can fluctuate based on changes in our credit ratings. As such, our borrowing cost under these credit arrangements will be subject to both fluctuations in interest rates and changes in our credit ratings. At June 30, 2011, the borrowing rates under these debt instruments were: for our floating rate senior notes due 2014, LIBOR plus 0.85%; for our term loan due May 2012, LIBOR plus 0.40%; for our senior unsecured revolving credit facility, LIBOR plus 0.40%; and for our secured receivables credit facility, 1.10%. At June 30, 2011, the weighted average LIBOR was 0.2%. As of June 30, 2011, \$200 million, \$742 million, and \$85 million were outstanding under our floating rate senior notes due 2014, our term loan due May 2012, and our \$525 million secured receivables credit facility, respectively. There were no borrowings outstanding under our \$750 million senior unsecured revolving credit facility as of June 30, 2011.

We seek to mitigate the variability in cash outflows that result from changes in interest rates by maintaining a balanced mix of fixed-rate and variable-rate debt obligations. In order to achieve this objective, we have entered into interest rate swaps. Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements are recognized as an adjustment to interest expense.

In March 2011, we entered into various fixed-to-variable interest rate swap agreements which have a notional amount totaling \$200 million and a variable interest rate based on six-month LIBOR plus 0.54%. These derivative financial instruments are accounted for as fair value hedges of a portion of our senior notes due 2016. In addition, in previous years we entered into various fixed-to-variable interest rate swap agreements with a notional amount of \$350 million and a variable interest rate based on one-month LIBOR plus 1.33% that were accounted for as fair value hedges of a portion of our senior notes due 2020. Based on our net exposure to interest rate changes, a hypothetical 10% change in interest rates on our variable rate indebtedness (representing 3 basis points) would impact annual interest expense by approximately \$0.4 million, assuming no changes to the debt outstanding at June 30, 2011.

The fair value of the fixed-to-variable interest rate swap agreements related to our senior notes due 2016 and our senior notes due 2020 was an asset of \$18.9 million at June 30, 2011. A hypothetical 10% change in interest rates (representing 25 basis points) would potentially change the fair value of the asset by \$10 million.

For further details regarding our outstanding debt, see Note 10 to the consolidated financial statements included in our 2010 Annual Report on Form 10-K for the year ended December 31, 2010 and Note 8 to the interim consolidated financial statements. For details regarding our financial instruments, see Note 9 to the interim consolidated financial statements.

#### *Risk Associated with Investment Portfolio*

Our investment portfolio includes equity investments in publicly held companies that are classified as available-for-sale securities and other strategic equity holdings in privately held companies. These securities are exposed to price fluctuations and are generally concentrated in the life sciences industry. The carrying values of our available-for-sale equity securities and privately held securities were \$15.1 million at June 30, 2011.

We regularly evaluate the fair value measurements of our equity investments to determine if losses in value are other than temporary and if an impairment loss has been incurred. The evaluation considers whether the security has the ability to recover and, if so, the estimated recovery period. Other factors that are considered in this evaluation include the amount of the other-than-temporary decline and its duration, the issuer's financial condition and short-term prospects, and whether the market decline was caused by overall economic conditions or conditions specific to the individual security.

We do not hedge our equity price risk. The impact of an adverse movement in equity prices on our holdings in privately held companies cannot be easily quantified, as our ability to realize returns on investments depends on, among other things, the enterprises' ability to raise additional capital or derive cash inflows from continuing operations or through liquidity events such as initial public offerings, mergers or private sales.

## Liquidity and Capital Resources

### *Cash and Cash Equivalents*

Cash and cash equivalents at June 30, 2011 totaled \$184 million, compared to \$449 million at December 31, 2010. Cash and cash equivalents consist of cash and highly liquid short-term investments. For the six months ended June 30, 2011, cash flows from operating activities of \$220 million, together with cash on hand and cash flows from financing activities of \$523 million, were used to fund investing activities of \$1.0 billion. Cash and cash equivalents at June 30, 2010 totaled \$448 million, compared to \$534 million at December 31, 2009. For the six months ended June 30, 2010, cash flows from operating activities of \$448 million, together with cash on hand, were used to fund investing and financing activities of \$92 million and \$443 million, respectively.

### *Cash Flows from Operating Activities*

Net cash provided by operating activities for the six months ended June 30, 2011 was \$220 million compared to \$448 million in the prior year period. For the six months ended June 30, 2011, cash flows from operating activities included the second quarter payment to Medi-Cal, the California Medicaid program, of \$241 million in connection with the settlement of the California Lawsuit (see Note 12 to the interim consolidated financial statements), or \$194 million net of an associated reduction in second quarter estimated tax payments. In addition, 2011 cash flows from operating activities were reduced by \$25 million of payments related to transaction and integration costs associated with the acquisitions of Athena and Celera, or \$18 million net of an associated reduction in estimated tax payments. After giving consideration to the net settlement and transaction and integration payments, underlying cash flows from operating activities for the six months ended June 30, 2011 decreased by \$16.7 million in comparison to the prior year. This decrease was primarily driven by operating performance and an increase in interest payments, partially offset by a reduction in estimated tax payments. Days sales outstanding, a measure of billing and collection efficiency, were 44 days at both June 30, 2011 and December 31, 2010, compared to 42 days at June 30, 2010.

### *Cash Flows from Investing Activities*

Net cash used in investing activities for the six months ended June 30, 2011 was \$1.0 billion, consisting principally of \$740 million related to the acquisition of Athena and \$396 million net of cash acquired related to the acquisition of Celera, or \$183 million net of cash and \$213 million of short-term marketable securities acquired. A liability of \$159 million, representing merger consideration related to shares of Celera which had not been surrendered, is included in accounts payable and accrued expenses at June 30, 2011. Proceeds from the sale of the short-term marketable securities, acquired as part of the Celera acquisition, were used to repay borrowings outstanding under our secured receivables credit facility and our unsecured revolving credit facility in the second quarter of 2011. In addition, cash flows from investing activities for the six months ended June 30, 2011 included capital expenditures of \$79 million. Net cash used in investing activities for the six months ended June 30, 2010 was \$92 million, and consisted principally of capital expenditures.

### *Cash Flows from Financing Activities*

Net cash provided by financing activities for the six months ended June 30, 2011 was \$523 million, consisting primarily of net increases in debt of \$1.3 billion, and proceeds from the exercise of stock options and related tax benefits totaling \$102 million, partially offset by purchases of treasury stock of \$835 million, dividend payments of \$33 million, distributions to noncontrolling interests of \$17 million and \$10 million of payments primarily related to debt issuance costs incurred in connection with our senior notes offering in the first quarter of 2011. The net increase in debt consists of \$2.4 billion of borrowings and \$1.1 billion of repayments.

In February 2011, borrowings of \$500 million under our secured receivables credit facility and \$75 million under our senior unsecured credit facility, together with \$260 million of cash on hand, were used to fund purchases of treasury stock totaling \$835 million. In addition, we completed a \$1.25 billion senior notes offering in March 2011 (the "2011 Senior Notes"). We used \$485 million of the \$1.24 billion in net proceeds from the 2011 Senior Notes offering, together with \$90 million of cash on hand, to fund the repayment of \$500 million outstanding under our secured receivables credit facility, and the repayment of \$75 million outstanding under our unsecured revolving credit facility. The remaining portion of the net proceeds from the 2011 Senior Notes offering were used to fund our acquisition of Athena in April 2011 (see Note 4 and Note 8 to the interim financial statements for further details).

During the second quarter of 2011, \$585 million and \$30 million of borrowings under our secured receivables credit facility and our unsecured revolving credit facility, respectively, together with cash on hand, were used to fund the acquisition of Celera in May 2011 (see Note 4 to the interim financial statements for further details). During the second quarter of 2011, proceeds from the sale of short-term marketable securities acquired as part of the Celera acquisition totaling \$214 million, together with cash on hand, were used to fund \$500 million and \$30 million of debt repayments under our secured receivables credit facility and our unsecured revolving credit facility, respectively.

Net cash used in financing activities for the six months ended June 30, 2010 was \$443 million, consisting primarily of purchases of treasury stock totaling \$426 million, dividend payments of \$36 million and distributions to noncontrolling interests of \$17 million, partially offset by \$40 million in proceeds from the exercise of stock options, including related tax benefits.

#### *Dividends*

During each of the quarters of 2011 and 2010, our Board of Directors declared a quarterly cash dividend of \$0.10 per common share. We expect to fund future dividend payments with cash flows from operations, and do not expect the dividend to have a material impact on our ability to finance future growth.

#### *Share Repurchases*

In January 2011, our Board of Directors authorized \$750 million of additional share repurchases of our common stock, increasing our total available authorization at that time to \$1 billion. The share repurchase authorization has no set expiration or termination date.

For the six months ended June 30, 2011, we repurchased 15.4 million shares of our common stock from SB Holdings Capital Inc., a wholly-owned subsidiary of GlaxoSmithKline plc., at an average price of \$54.30 per share for a total of \$835 million. At June 30, 2011, \$165 million remained available under the share repurchase authorizations.

For the three months ended June 30, 2010, we repurchased 3.3 million shares of our common stock at an average price of \$53.36 per share for \$175 million. For the six months ended June 30, 2010, we repurchased 7.7 million shares of our common stock at an average price of \$55.00 per share for \$426 million, including 4.5 million shares purchased in the first quarter at an average price of \$56.21 per share for \$251 million under an accelerated share repurchase transaction with a bank.

#### *Contractual Obligations and Commitments*

The following table summarizes certain of our contractual obligations as of June 30, 2011:

Contractual Obligations	Payments due by period				
	Total	Remainder of 2011	(in thousands)		
			1-3 years	3-5 years	After 5 years
Outstanding debt	\$ 4,286,269	\$ 426,269	\$ 560,000	\$ 700,000	\$ 2,600,000
Capital lease obligations	47,042	4,164	15,941	12,179	14,758
Interest payments on outstanding debt	2,235,864	85,825	308,932	302,872	1,538,235
Operating leases	639,741	96,620	256,605	134,453	152,063
Purchase obligations	71,890	24,997	36,693	9,444	756
Merger consideration obligation	158,560	158,560	—	—	—
<b>Total contractual obligations</b>	<b>\$ 7,439,366</b>	<b>\$ 796,435</b>	<b>\$ 1,178,171</b>	<b>\$ 1,158,948</b>	<b>\$ 4,305,812</b>

Interest payments on our long-term debt have been calculated after giving effect to our interest rate swap agreements, using the interest rates as of June 30, 2011 applied to the June 30, 2011 balances, which are assumed to remain outstanding through their maturity dates.

A full description of the terms of our indebtedness and related debt service requirements and our future payments under certain of our contractual obligations is contained in Note 10 to the Consolidated Financial Statements in our 2010 Annual Report on Form 10-K, as updated in Note 8 to the interim consolidated financial statements. A full discussion and analysis regarding our minimum rental commitments under noncancelable operating leases and noncancelable commitments to purchase product or services at December 31, 2010 is contained in Note 15 to the Consolidated Financial Statements in our 2010 Annual Report on Form 10-K. See Note 4 to the interim consolidated financial statements for a discussion with respect to merger consideration related to shares of Celera which had not been surrendered as of June 30, 2011.

As of June 30, 2011, our total liabilities associated with unrecognized tax benefits were approximately \$213 million, which were excluded from the table above. We believe it is reasonably possible that these liabilities may decrease by up to \$26 million within the next twelve months, primarily as a result of the expiration of statutes of limitations, settlements and/or the conclusion of tax examinations on certain tax positions. For the remainder, we cannot make reasonably reliable estimates of the timing of the future payments of these liabilities. See Note 5 to the Consolidated Financial Statements in our 2010 Annual Report on Form 10-K for information regarding our contingent tax liability reserves.

Our credit agreements and our term loan due May 2012 contain various covenants and conditions, including the maintenance of certain financial ratios, that could impact our ability to, among other things, incur additional indebtedness. As of June 30, 2011, we were in compliance with the various financial covenants included in our credit agreements and we do not expect these covenants to adversely impact our ability to execute our growth strategy or conduct normal business operations.

#### *Unconsolidated Joint Ventures*

We have investments in unconsolidated joint ventures in Phoenix, Arizona; Indianapolis, Indiana; and Dayton, Ohio, which are accounted for under the equity method of accounting. We believe that our transactions with our joint ventures are conducted at arm's length, reflecting current market conditions and pricing. Total net revenues of our unconsolidated joint ventures equal less than 6% of our consolidated net revenues. Total assets associated with our unconsolidated joint ventures are less than 2% of our consolidated total assets. We have no material unconditional obligations or guarantees to, or in support of, our unconsolidated joint ventures and their operations.

#### *Requirements and Capital Resources*

We estimate that we will invest approximately \$200 million during 2011 for capital expenditures, including assets under capitalized leases, to support and expand our existing operations, principally related to investments in information technology, equipment and facility upgrades. We expect to fund the repayment of the current portion of our long-term debt using cash on hand and existing credit facilities.

Accounts payable and accrued expenses at June 30, 2011 included a liability of \$159 million representing merger consideration related to shares of Celera which had not been surrendered as of June 30, 2011. We expect to fund the payment of the remaining merger consideration with cash on hand and existing credit facilities.

As of June 30, 2011, \$1.2 billion of borrowing capacity was available under our existing credit facilities, consisting of \$440 million available under our secured receivables credit facility and \$750 million available under our senior unsecured revolving credit facility.

We believe the banks participating in our various credit facilities are predominantly highly-rated banks, and that the borrowing capacity under the credit facilities described above is currently available to us. Should one or several banks no longer participate in either of our credit facilities, we would not expect it to impact our ability to fund operations. We expect that we will be able to replace our existing secured receivables credit facility and our senior unsecured revolving credit facility with alternative arrangements prior to their expiration.

We believe that cash and cash equivalents on hand and cash from operations, together with our borrowing capacity under our credit facilities, will provide sufficient financial flexibility to meet seasonal working capital requirements, capital expenditures, debt service requirements and other obligations, cash dividends on common shares, share repurchases and additional growth opportunities for the foreseeable future. We believe that our credit profile should

provide us with access to additional financing, if necessary, to fund growth opportunities that cannot be funded from existing sources.

### **Impact of New Accounting Standards**

In May 2011, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting standards related to fair value measurements. In June 2011, the FASB issued an amendment to the accounting standards related to the presentation of comprehensive income. The impact of these accounting standards is discussed in Note 2 to the interim financial statements.

### **Forward-Looking Statements**

Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue." These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could significantly cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Risks and uncertainties that may affect our future results include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business," "Risk Factors," "Cautionary Factors That May Affect Future Results," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Quantitative and Qualitative Disclosures About Market Risk" in our 2010 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in our 2011 Quarterly Reports on Form 10-Q and other items throughout the 2010 Form 10-K and our 2011 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

See Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations."

### **Item 4. Controls and Procedures**

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended). Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report.

During the second quarter of 2011, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II - OTHER INFORMATION

### Item 1. Legal Proceedings

See Note 12 to the interim consolidated financial statements for information regarding the status of legal proceedings involving the Company.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The table below sets forth the information with respect to purchases made by or on behalf of the Company of its common stock during the second quarter of 2011.

#### ISSUER PURCHASES OF EQUITY SECURITIES

Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in thousands)
April 1, 2011 – April 30, 2011				
Share Repurchase Program (A)	—	\$ —	—	\$ 165,049
Employee Transactions (B)	1,258	\$ 56.67	N/A	N/A
May 1, 2011 – May 31, 2011				
Share Repurchase Program (A)	—	\$ —	—	\$ 165,049
Employee Transactions (B)	3,532	\$ 57.23	N/A	N/A
June 1, 2011 – June 30, 2011				
Share Repurchase Program (A)	—	\$ —	—	\$ 165,049
Employee Transactions (B)	—	\$ —	N/A	N/A
Total				
Share Repurchase Program (A)	—	\$ —	—	\$ 165,049
Employee Transactions (B)	4,790	\$ 57.08	N/A	N/A

- (A) In January 2011, our Board of Directors authorized the Company to repurchase an additional \$750 million of the Company's common stock, increasing the total available authorization at that time to \$1 billion. Since the share repurchase program's inception in May 2003, our Board of Directors has authorized \$4.5 billion of share repurchases of our common stock through June 30, 2011. The share repurchase authorization has no set expiration or termination date.
- (B) Includes: (1) shares delivered or attested to in satisfaction of the exercise price and/or tax withholding obligations by holders of stock options (granted under the Company's Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan, collectively the "Stock Compensation Plans") who exercised options; (2) restricted common shares withheld (under the terms of grants under the Stock Compensation Plans) to offset tax withholding obligations that occur upon vesting and release of the restricted common shares; and (3) shares withheld (under the terms of grants under the Stock Compensation Plans) to offset tax withholding obligations that occur upon the delivery of common shares underlying restricted stock units and performance share units.

**Item 6. Exhibits****Exhibits:**

31.1	Rule 13a-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a) Certification of Chief Financial Officer
32.1	Section 1350 Certification of Chief Executive Officer
32.2	Section 1350 Certification of Chief Financial Officer
101.INS	dgx-20110630.xml
101.SCH	dgx-20110630.xsd
101.CAL	dgx-20110630_cal.xml
101.DEF	dgx-20110630_def.xml
101.LAB	dgx-20110630_lab.xml
101.PRE	dgx-20110630_pre.xml



## Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

July 27, 2011

Quest Diagnostics Incorporated

By /s/ Surya N. Mohapatra

Surya N. Mohapatra, Ph.D.  
Chairman of the Board, President and  
Chief Executive Officer

By /s/ Robert A. Hagemann

Robert A. Hagemann  
Senior Vice President and  
Chief Financial Officer

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Surya N. Mohapatra, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Quest Diagnostics Incorporated;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

July 27, 2011

By /s/ Surya N. Mohapatra

Surya N. Mohapatra, Ph.D.  
Chairman of the Board, President and  
Chief Executive Officer

---

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert A. Hagemann, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Quest Diagnostics Incorporated;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

July 27, 2011

By /s/ Robert A. Hagemann

Robert A. Hagemann  
Senior Vice President and  
Chief Financial Officer

---

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. § 1350,  
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended June 30, 2011 of Quest Diagnostics Incorporated, as being filed with the Securities and Exchange Commission concurrently herewith, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. § 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Quest Diagnostics Incorporated.

Dated: July 27, 2011

/s/ Surya N. Mohapatra

Surya N. Mohapatra, Ph.D.  
Chairman of the Board, President and  
Chief Executive Officer

---

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. § 1350,  
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended June 30, 2011 of Quest Diagnostics Incorporated, as being filed with the Securities and Exchange Commission concurrently herewith, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. § 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Quest Diagnostics Incorporated.

Dated: July 27, 2011

/s/ Robert A. Hagemann

Robert A. Hagemann  
Senior Vice President and  
Chief Financial Officer

---